Biological fluid treatment system

Abstract

Disclosed herein are systems, methods, and apparatuses for processing biological fluids. In some embodiments, the biological fluid processing system includes a processing device, a platform, an array of light sources, and a display. In some embodiments, the biological fluid processing system includes a scanner.

Description

[0001] Cross-references to related applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 865,207, filed June 22, 2019; U.S. Provisional Patent Application No. 62 / 869,544, filed July 1, 2019; and U.S. Provisional Patent Application No. 62 / 986,593, filed March 6, 2020, the disclosures of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present invention generally relates to systems, methods and apparatus for treating biological fluids (including mixtures of biological fluids and photochemical agents) with light. Background Technology

[0004] Systems and methods for treating biological fluids with light are well known. For example, U.S. Patents 7,459,695, 6,986,867, and 5,593,823 describe a system for treating biological fluids with light to inactivate pathogens in the biological fluid. Light is emitted within a selected wavelength range that is effective in inactivating pathogens in the biological fluid (particularly by photochemical inactivation of pathogens). Other systems and methods for treating biological fluids with light may include, for example, those described in U.S. Patents 6,843,961, 7,829,867, 9,320,817, and 8,778,263, and Schlenke, 2014, Transfus. Med. Hemother. 41:309-325.

[0005] For blood products, including, for example, platelets and plasma components and their derivatives, it is important to ensure that the blood products are free of pathogens to minimize the risk of infection to individuals receiving the blood products. Detection of the presence of pathogens in blood is limited by the available pathogens and the sensitivity of the assay. As an alternative or supplement to testing for pathogens, various compound-based (e.g., chemical, photochemical) inactivation methods are known in the art to inactivate pathogens and reduce the risk of transfusion-transmitted infections (e.g., disclosed in Schlenke et al., Transfus Med Hemother, 2014, 41, 309-325 and Prowse, Vox Sanguinis, 2013, 104, 183-199). Psoralen-based and ultraviolet light-based photochemical pathogen inactivation systems for processing blood products include commercially available... The Blood System (Cerus Corporation) utilizes disposable processing kits and an ultraviolet irradiation device (INT-100). In the processing kit, blood products such as plasma or platelets are mixed with psoralen and amotosalen, then irradiated with ultraviolet A light. Residual amotosalen and its photoproducts are subsequently removed using the compound adsorption (CAD) section of the processing kit. A variety of different disposable processing kits can be used, depending on the type of blood product to be processed and its specific properties, such as volume and platelet count. Different irradiation requirements may limit the ability to process multiple processing kits in the same irradiation device, thus affecting the efficiency of the blood collection center. Furthermore, previous irradiation systems could be horizontally wide and limited to processing chambers in only one horizontal layer.

[0006] While prior systems and methods for processing biological fluids (such as blood products described herein) have generally performed satisfactorily, there is a desire to develop improved systems and methods, including those disclosed herein that include multiple processing chambers and design features that can provide various advantageous benefits for higher throughput processing of biological fluids, ease of use by operators, and / or reduction of user operator errors that may affect the systems being processed and / or the biological fluids being processed. Summary of the Invention

[0007] This document discloses systems, methods, and apparatus for processing biological fluids. In some embodiments, the biological fluid processing system includes: a processing chamber configured to receive biological fluid; a platform configured to carry the biological fluid and position it within the processing chamber; a light source array positioned to illuminate the biological fluid in the processing chamber; and a display configured to display a graphical user interface (GUI). In some embodiments, the biological fluid processing system includes a scanner configured to acquire identification information associated with a first biological fluid, a second biological fluid, or both the first and second biological fluids.

[0008] In some embodiments, the biofluid processing system includes: a first processing chamber configured to receive a first biofluid; a second processing chamber configured to receive a second biofluid; a first platform configured to hold the first biofluid and positioned within the first processing chamber; a second platform configured to hold the second biofluid and positioned within the second processing chamber; a first light source array and a second light source array positioned to irradiate the first biofluid in the first processing chamber and the second light source array positioned to irradiate the second biofluid in the second processing chamber; a display; one or more processors; and a memory including instructions that, when executed by the one or more processors, cause the one or more processors to perform a method including providing a GUI for display on the display, the GUI including a plurality of GUI objects associated with processing the first biofluid by irradiation from the first light source array or with processing the second biofluid by irradiation from the second light source array.

[0009] In some embodiments, the first light source array and the second light source array are configured to irradiate the first biofluid and the second biofluid with ultraviolet light, respectively. In some embodiments, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 315 nm to about 350 nm. In some embodiments, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 330 nm to about 350 nm. In some embodiments, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 340 nm to about 350 nm. In some embodiments, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength in the range of 345 ± 5 nm. In some embodiments, each light source array includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 315 nm to about 335 nm. In some embodiments, each light source array includes a corresponding second light source channel configured to emit ultraviolet light from the array having a second peak wavelength, wherein the second peak wavelength differs from the first peak wavelength by at least 5 nanometers.

[0010] In some embodiments, for each light source array in the light source array, a corresponding first light source channel includes one or more light sources, each of which emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers. In some embodiments, for each light source array in the light source array, a corresponding second light source channel includes one or more light sources, each of which emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers.

[0011] In some embodiments, the system further includes: a third light source array facing in the opposite direction to the first light source array and positioned to irradiate a first biological fluid in a first processing chamber; and a fourth light source array facing in the opposite direction to the second light source array and positioned to irradiate a second biological fluid in a second processing chamber; wherein the method further includes providing a graphical user interface (GUI) for display on a display, the graphical user interface including a plurality of GUI objects associated with processing the first biological fluid by irradiation from the third light source array or with processing the second biological fluid by irradiation from the fourth light source array.

[0012] In some embodiments, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 315 nm to about 350 nm. In some embodiments, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 330 nm to about 350 nm. In some embodiments, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 340 nm to about 350 nm. In some embodiments, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength in the range of 345 ± 5 nm. In some embodiments, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 315 nm to about 335 nm. In some embodiments, each of the third and fourth light source arrays includes a corresponding second light source channel configured to emit ultraviolet light from the array having a second peak wavelength, wherein the second peak wavelength differs from the first peak wavelength by at least 5 nanometers.

[0013] In some embodiments, for each of the third and fourth light source arrays, the corresponding first light source channel includes one or more light sources, each of which emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers. In some embodiments, for each of the third and fourth light source arrays, the corresponding second light source channel includes one or more light sources, each of which emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers.

[0014] In some implementations, each of the light source arrays (e.g., a first array, a second array, a third array, a fourth array) includes one or more light sources, each of which is a light-emitting diode, and wherein for each light source array, the corresponding ultraviolet light is emitted by the corresponding one or more light sources.

[0015] In some implementations, the first platform is slidably movable to introduce and remove a first biological fluid into and out of a first processing chamber, and the second platform is slidably movable to introduce and remove a second biological fluid into and out of a second processing chamber.

[0016] In some implementations, the system also includes a housing configured to enclose a first processing chamber, a second processing chamber, a first platform, a second platform, a first light source array, a second light source array, a display, one or more processors, and a memory.

[0017] In some embodiments, the system further includes a scanner configured to acquire identification information associated with a first biological fluid, a second biological fluid, or both. In some embodiments, the scanner is one of a group including a barcode scanner, a QR code scanner, and an RFID scanner. In some embodiments, the identification information is transmitted in the form of transmissible radio waves from an RFID tag on at least one of a container (e.g., a single container) for containing the first or second biological fluid, or a container in a multi-container assembly for containing the first or second biological fluid, and the method further includes acquiring the identification information transmitted radio waves from the RFID tag on the container via the scanner. In some embodiments, the identification information is a visible barcode or QR code on the container (e.g., a single container) for containing the first or second biological fluid, and the method further includes acquiring the barcode or QR code on the container via the scanner. In some embodiments, the identification information is a visible barcode or QR code on at least one of the containers in a multi-container assembly for containing a first or second biological fluid, and the method further includes obtaining the barcode or QR code on at least one of the containers via a scanner. In some embodiments, the scanner is configured to obtain identification information transmitted in the form of radio waves from an RFID tag on either the container (e.g., a single container) for containing the first or second biological fluid or on at least one of the containers in a multi-container assembly for containing the first or second biological fluid when the container is positioned on a first or second platform. In some embodiments, the scanner is configured to obtain visual identification information on the container when the container (e.g., a single container) for containing the first or second biological fluid is positioned on a first or second platform. In some embodiments, the scanner is configured to obtain visual identification information on at least one of the containers when the one or more containers in a multi-container assembly for containing the first or second biological fluid are positioned on a first or second platform. In some implementations, the identification information is in the form of multiple sets of identification information visible on a container (e.g., a single container) used to contain a first biological fluid or a second biological fluid, and the scanner is a multi-scan scanner configured to acquire multiple sets of identification information (e.g., each of the multiple sets of identification information, or all of the multiple sets of identification information) in a multi-scan operation.In some embodiments, the identification information is in the form of multiple sets of identification information visible on one or more containers of a multi-container assembly for containing a first or second biological fluid, and the scanner is a multi-scan scanner configured to acquire multiple sets of identification information (e.g., each of the multiple sets of identification information, or all of the multiple sets of identification information) during a multi-scan operation. In some embodiments, the identification information is in a transmissible form from a tag on a container (e.g., a single container) for containing the first or second biological fluid, and the scanner is a multi-scan scanner configured to acquire multiple sets of identification information (e.g., each of the multiple sets of identification information, or all of the multiple sets of identification information) during a multi-scan operation. In some embodiments, the identification information is in a transmissible form from a tag on one or more containers of a multi-container assembly for containing the first or second biological fluid, and the scanner is a multi-scan scanner configured to acquire multiple sets of identification information (e.g., each of the multiple sets of identification information, or all of the multiple sets of identification information) during a multi-scan operation.

[0018] In some embodiments, the scanner is integrated or embedded in a fixed location within a housing and coupled to one or more processors. In some embodiments, the scanner is located within a first processing chamber, a second processing chamber, or both. In some embodiments, the scanner is located at a first opening in the first processing chamber or a second opening in the second processing chamber. In some embodiments, the scanner is located outside the first and second processing chambers. In some embodiments, the scanner is a handheld scanner wirelessly coupled to the one or more processors. In some embodiments, the scanner is a handheld scanner coupled to the one or more processors via a wired connection.

[0019] In some embodiments, the first and second treatment chambers are arranged horizontally such that the first and second biofluids lie in the same plane when positioned on the first and second platforms, respectively. In some embodiments, the first and second treatment chambers are arranged vertically such that the first and second biofluids lie in parallel planes when positioned on the first and second platforms, respectively.

[0020] In some embodiments, the system further includes a first panel movable between a closed position and an open position, wherein the first panel covers a first opening to a first processing chamber in the closed position, and exposes the first opening to the first processing chamber in the open position, wherein the exterior of the first panel includes one or more of a protruding handle and a recessed handle. In some embodiments, the system further includes a first panel movable between a closed position and an open position, wherein the first panel covers the first opening to the first processing chamber in the closed position, and exposes the first opening to the first processing chamber in the open position, wherein the entire exterior of the first panel does not have any handle. In some embodiments, the first panel is configured to be locked to remain in the closed position and is configured to unlock in response to input. In some embodiments, the input is user input, such as manual input by the user on a touchscreen (e.g., touch or hover), a user's voice command (e.g., detected by a microphone), or a user's visual movement (e.g., hand movement or gesture, object in a swipe motion) to unlock the panel.

[0021] In some embodiments, the first platform includes a first panel. In some embodiments, the first platform includes: an outer region comprising: the first panel movable between a closed position and an open position, the outer region being configured to remain in a fixed position when the first panel is in the closed position, and a first support structure; and an inner region configured to move during a period when the outer region is in a fixed position to agitate a first biofluid, wherein the first support structure of the outer region structurally supports the inner region. In some embodiments, the inner region of the first platform configured to move to agitate the first biofluid includes an inner region assembly comprising: one or more removable inner region portions configured to carry a container containing the first biofluid; and an inner region support structure structurally supporting the one or more removable inner region portions, and the inner region support structure being movable to agitate the first biofluid carried by the one or more removable inner region portions.

[0022] In some embodiments, the outer region includes a motor configured to generate motion, wherein the inner region is configured to agitate the first biofluid based on the motion generated by the motor. In some embodiments, the system is configured to control (e.g., adjustably control) one or more aspects of movement of the inner region to agitate the first biofluid, such as offset, velocity, acceleration, and deceleration. In some embodiments, the motor is located to the right or left of where the first platform will carry the first biofluid. In some embodiments, the motor is located in front of or behind where the first platform will carry the first biofluid.

[0023] In some embodiments, the second platform includes: a second panel movable between a closed position and an open position, wherein the second panel covers a second opening leading to a second processing chamber in the closed position, and exposes the second opening leading to the second processing chamber in the open position; an outer region including: the second panel movable between a closed position and an open position, the outer region configured to remain in a fixed position when the second panel is in the closed position, and a second support structure; and an inner region configured to move to agitate a second biofluid during a period when the outer region is in a fixed position, wherein the second support structure of the output region structurally supports the inner region. In some embodiments, the inner region of the second platform configured to move to agitate the second biofluid includes an inner region assembly including: one or more removable inner region portions configured to carry a container containing the second biofluid; and an inner region support structure structurally supporting the one or more removable inner region portions, and the inner region support structure being movable to agitate the second biofluid carried by the one or more removable inner region portions.

[0024] In some embodiments, the first platform and the second platform each include a first compartment and a second compartment, the first compartment and the second compartment being configured to carry a multi-container assembly containing a biofluid for the respective platform, wherein the first compartment of the first platform is configured to carry a first container of the first multi-container assembly, the first container containing the first biofluid, and wherein the first compartment is positioned such that when the first platform is positioned in a first processing chamber, a first light source array is configured to irradiate the first container; wherein the second compartment of the first platform is configured to carry one or more additional containers of the first multi-container assembly, the one or more additional containers not containing the first biofluid, and wherein the second compartment is positioned such that when the first platform is positioned in a first processing chamber... When the second platform is positioned in the second processing chamber, the first light source array is not configured to illuminate the one or more additional containers; wherein the first compartment of the second platform is configured to carry a first container of the second multi-container assembly, the first container containing the second biological fluid, and wherein the first compartment is positioned such that the second light source array is configured to illuminate the first container when the second platform is positioned in the second processing chamber; and wherein the second compartment of the second platform is configured to carry one or more additional containers of the second multi-container assembly, the one or more additional containers not containing the second biological fluid, and wherein the second compartment is positioned such that when the second platform is positioned in the second processing chamber, the second light source array is not configured to illuminate the one or more additional containers.

[0025] In some embodiments, the display is a touchscreen configured to display a GUI comprising multiple GUI objects, and the GUI objects respond to touch input on the touchscreen. In some embodiments, the method further includes: receiving input associated with selection of a GUI object; and performing a biofluid processing operation in response to receiving the input.

[0026] In some embodiments, any system provided herein (e.g., the aforementioned system) can perform a method of treating one or more biological fluids, the method comprising: irradiating a first biological fluid of the one or more biological fluids with ultraviolet light emitted by a group of one or more first light sources (e.g., ultraviolet light having a first peak wavelength of about 315 nm to about 350 nm), wherein the first biological fluid is mixed with a pathogen inactivating compound (e.g., a photoactive pathogen inactivating compound, psoralen, amtoxalin), wherein: 1) each of the one or more first light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nm, and / or 2) each of the one or more first light sources is a light-emitting diode (LED); and wherein the duration and intensity of irradiation of the first biological fluid are sufficient to inactivate pathogens in the first biological fluid. In some embodiments, the method of treating one or more biological fluids may further include: irradiating a second biological fluid in the one or more biological fluids with ultraviolet light emitted by one or more second light sources (e.g., ultraviolet light having a second peak wavelength of about 315 nm to about 350 nm), wherein the second biological fluid is mixed with a pathogen inactivating compound (e.g., a photoactive pathogen inactivating compound, psoralen, amtoxalin), wherein: 1) each of the one or more second light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nm, and / or 2) each of the one or more second light sources is a light-emitting diode (LED); and wherein the duration and intensity of irradiation of the second biological fluid are sufficient to inactivate the pathogens in the second biological fluid.

[0027] In some embodiments, each of the first platform and the second platform is configured to hold a first biofluid and a second biofluid, respectively, in a first flexible container and a second flexible container, each flexible container having a volumetric capacity of up to about 3000 mL. In some embodiments, each of the first platform and the second platform is configured to hold a first biofluid and a second biofluid, respectively, in a first flexible container and a second flexible container, each flexible container having a volumetric capacity of up to about 1500 mL. In some embodiments, each of the first platform and the second platform is configured to hold a first biofluid and a second biofluid, respectively, in a first flexible container and a second flexible container, each flexible container having a volumetric capacity of up to about 1000 mL.

[0028] In some embodiments, the system includes a heating unit and / or a cooling unit configured to regulate or set the temperature of a first processing chamber, wherein the method further includes controlling the heating unit / cooling unit to maintain the temperature of the first biological fluid below 2°C during treatment by irradiation from a first light source array. In some embodiments, the method further includes controlling the system to maintain the temperature of the first biological fluid below 2°C during treatment by irradiation from a first light source array. In some embodiments, the system includes a heating unit and / or a cooling unit configured to regulate or set the temperature of a second processing chamber, wherein the method further includes controlling the heating unit / cooling unit to maintain the temperature of the second biological fluid below 2°C during treatment by irradiation from a second light source array. In some embodiments, the method further includes controlling the system to maintain the temperature of the second biological fluid below 2°C during treatment by irradiation from a second light source array.

[0029] In some embodiments, the housing has a maximum horizontal width in the range of 30cm-45cm. In some embodiments, the system is configured to operate within a target operating space such that there is an empty space of 20cm or less on both the left and right sides of the housing.

[0030] In some embodiments, the system further includes one or more proximity panels configured to provide proximity to one or more of the first light source array, the second light source array, and / or the one or more processors. In some embodiments, the system further includes one or more front proximity panels configured to provide proximity to one or more of the first light source array, the second light source array, and / or the one or more processors. In some embodiments, the system further includes one or more side proximity panels configured to provide proximity to one or more of the first light source array, the second light source array, and / or the one or more processors.

[0031] In another aspect, this disclosure provides a method for treating a biological fluid, the method comprising irradiating the biological fluid with any system provided herein (e.g., the aforementioned system, the system disclosed below), the duration and intensity of which are sufficient to inactivate pathogens in the biological fluid (e.g., if present in the biological fluid). In some embodiments, this disclosure provides a method for treating a biological fluid, the method comprising: providing a biological fluid mixed with a pathogen inactivating compound (e.g., a photoactive pathogen inactivating compound, psoralen, amtosalin), and irradiating the biological fluid with any system provided herein (e.g., the aforementioned system), the duration and intensity of which are sufficient to inactivate pathogens in the biological fluid (e.g., if present in the biological fluid). In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources (e.g., ultraviolet A, ultraviolet B, ultraviolet C, having a first peak wavelength of about 315 nm to about 350 nm), wherein: 1) each of the one or more first light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nm, and / or 2) each of the one or more first light sources is a light-emitting diode (LED). In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 315 nm to about 350 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 330 nm to about 350 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 340 nm to about 350 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 345 nm to about 350 nm. + The biological fluid is irradiated with ultraviolet light having a first peak wavelength in the range of 5 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light having a first peak wavelength of about 315 nm to about 335 nm emitted by one or more first light sources. In some embodiments, the biological fluid is irradiated with ultraviolet light having a first peak wavelength emitted by one or more first light sources and ultraviolet light having a second peak wavelength from one or more second light sources, wherein the second peak wavelength differs from the first peak wavelength by at least 5 nm. In some embodiments, the duration and intensity of irradiation provide approximately 0.5 J / cm² of ultraviolet light irradiating the biological fluid. 2 Or greater (e.g., about 0.5 J / cm) 2 Approximately 50 J / cm 2 The total dose. In some embodiments, the intensity is 1-1000 mW / cm. 2 (For example, 1-100mW / cm) 2In some embodiments, the duration is from 1 second to 2 hours (e.g., 1 minute to 60 minutes). In some embodiments, the method of treating the biological fluid is sufficient to inactivate at least 1 log of pathogens in the biological fluid. In some embodiments, the method of treating the biological fluid is sufficient to inactivate at least 4 log of pathogens in the biological fluid. In some embodiments, the biological fluid is a blood product (e.g., platelets, plasma). Attached Figure Description

[0032] Figure 1 An exemplary system for processing biological fluids is shown.

[0033] Figure 2A-2C An exemplary system for processing biological fluids is shown.

[0034] Figures 3A-3B An exemplary system for processing biological fluids is shown.

[0035] Figure 4A-4L An exemplary system for processing biological fluids is shown.

[0036] Figure 5 This is a perspective view of an exemplary system for processing biological fluids.

[0037] Figure 6 This is a perspective view of an exemplary system for processing biological fluids.

[0038] Figure 7 A perspective view of an exemplary system for processing biological fluids is shown.

[0039] Figure 8 This is an example of a computing device according to one embodiment of the present disclosure.

[0040] Figures 9A-9F An exemplary system for processing biological fluids is shown.

[0041] Figure 10 An adjacent exemplary system for processing biological fluids is shown. Detailed Implementation

[0042] The following description is presented to enable those skilled in the art to make and use various embodiments. The descriptions of specific systems, apparatuses, methods, and applications are provided by way of example only. Various modifications to the examples described herein will be apparent to those skilled in the art, and the general principles defined herein can be applied to other examples and applications without departing from the spirit and scope of the various embodiments. Therefore, the various embodiments are not intended to be limited to the examples described and shown herein, but are to be accorded the scope consistent with the claims.

[0043] This document discloses systems, methods, and apparatus for processing biological fluids. In some embodiments, the biological fluid processing system includes: a processing chamber configured to receive biological fluid; a platform configured to carry the biological fluid and position it within the processing chamber; a light source array positioned to illuminate the biological fluid in the processing chamber; and a display configured to display a graphical user interface (GUI). In some embodiments, the biological fluid processing system includes a scanner configured to acquire identification information associated with a first biological fluid, a second biological fluid, or both the first and second biological fluids.

[0044] Biological fluids, such as blood and blood products, may contain contaminating pathogens due to infected donors or the introduction of pathogens during processing. Therefore, it may be necessary to subject such biological fluids to treatment processes that reduce the risk of contamination (e.g., pathogen inactivation, pathogen reduction). Ideally, such processes result in the inactivation of a wide range of pathogens (e.g., viruses, bacteria, parasites) that may be present in the biological fluid. The treatment process may also inactivate other undesirable substances, such as cells (e.g., leukocytes) and nucleic acids that may be present in the biological fluid. Advantageously, this disclosure provides improved systems, methods, and apparatus for treating biological fluids (including mixtures of biological fluids and photochemical agents) with light.

[0045] Figure 1An exemplary system 100 for processing biological fluids is shown. As used herein, “biological fluid” means any fluid found in or derived from an organism (e.g., human, animal, plant, microorganism), or any fluid containing one or more components (e.g., biological agents) found in, isolated from, or derived from an organism, including their synthetic (e.g., recombinant) forms. Biological fluids may include, but are not limited to, blood and blood products, vaccines, cells (e.g., primary cells, cell lines, cell cultures), natural and recombinant peptides or proteins (e.g., therapeutic agents, antibodies), bacterial cultures, viral suspensions, etc. As used herein, “blood products” means blood (e.g., whole blood) or components or derivatives of blood, such as red blood cells, white blood cells, platelets, plasma or components thereof (e.g., coagulation factors, albumin, fibrinogen), cryoprecipitate and cryo-mixed (e.g., cryo-restored) plasma, or one or more combinations of such components isolated from blood. In some embodiments, the biofluid may also include non-biofluids, such as physiological solutions (e.g., diluents), including but not limited to saline, buffer solutions, nutrient solutions, platelet additive solutions (PAS), and / or anticoagulant solutions. In some embodiments, when the biofluid is positioned in the chamber of a biofluid processing system (e.g., the biofluid is in a container such as a processing bag positioned on a platform), the biofluid is irradiated with light (e.g., visible light, ultraviolet light) with a specific spectral profile at a specific intensity for a defined time period.

[0046] System 100 includes a power switch 110, a display 120, a scanner 130, a platform 140, and a platform 150. Although Figure 1 System 100 includes the described elements, but examples of system 100 may include different combinations of the described elements or additional elements without departing from the scope of this disclosure. In some examples, system 100 may be coupled to a computing device (e.g., a computer, mobile device) (not shown) via a wired or wireless connection.

[0047] In some implementations, power is supplied to system 100 in response to an input to power switch 110. For example, power switch 110 may be a mechanical button. When system 100 is off, power is supplied to system 100 in response to the actuation of power switch 110 (e.g., system 100 is turned on). When system 100 is turned on, power supply to system 100 is stopped in response to the actuation of power switch 110 (e.g., system 100 is turned off). In some examples, during processing, system 100 remains on and does not turn off in response to the actuation of the power switch.

[0048] As another example, the power switch 110 may be a capacitive switch that can be activated by touch input (e.g., by placing a user's finger on the power switch). As another example, the power switch may be a button with two or more states. When the power switch is in a first position (e.g., not pressed, flipped to the first side), the power switch may be in an "off" state. When the power switch is in a second position (e.g., pressed, flipped to the second side), the power switch may be in an "on" state.

[0049] In some embodiments, display 120 is a touchscreen. For example, display 120 may be a capacitive touchscreen or a resistive touchscreen. In some examples, display 120 is configured to display a graphical user interface (GUI) for operating system 100. In some embodiments, display 120 is configured to receive input from scanner 130. In some embodiments, display 120 is configured to receive input on the GUI. For example, a GUI object can be selected from a plurality of GUI objects displayed on the GUI by providing manual input (e.g., touch input or hover input) from the user on the touchscreen. In response to receiving input, system 100 can perform an operation associated with the selected GUI object. For example, the GUI object may be associated with the initiation of a biological fluid treatment, and in response to receiving input to select the GUI object, system 100 initiates a process for treating the biological fluid. In some embodiments, display 120 is configured to display instructions (e.g., operator instructions) to a user operator on the GUI. In some embodiments, display 120 is configured to display input from scanner 130 to a user operator. In some embodiments, display 120 is configured to display sound input detected by an audio input (e.g., one or more microphones) and processed by one or more processors (e.g., speech-to-text conversion) into a visual form (e.g., command text, command code) on display 120 that the user can recognize as an input command, such as a user's voice command detected by one or more microphones (e.g., located in any arrangement inside, outside, and / or part of the outer housing of system 100) and converted by one or more processors into command text on display 120 that the user can recognize as an input command. In some embodiments, display 120 is configured to display input from a user's visual motion (e.g., hand movement or gesture, object in a swipe motion), which is detected by a motion sensor (e.g., one or more cameras) and processed by one or more processors (e.g., motion-to-text conversion, motion-to-graphics conversion) into a visual form (command text, command code, command icon, command graphic) on display 120 that the user can recognize as an input command. For example, a user's hand gesture (e.g., a hand in a swipe motion), which is detected by one or more cameras (e.g., cameras located inside, outside, and / or in any arrangement of the outer housing of system 100) and converted by one or more processors into visual command text or visual graphics on display 120 that the user can recognize as an input command. While in Figure 1 The diagram shows a display 120, but in some examples, system 100 may include more than one display.

[0050] By using a touchscreen as an input component and / or for input from the scanner 130, the user interface of system 100 can be simplified. For example, the use of a touchscreen reduces the need for physical buttons corresponding to features that can be performed similarly using a touchscreen. With a simplified user interface, biofluid processing using system 100 can be more efficient.

[0051] While power switch 110 and display 120 are described as elements of system 100 that can be configured to receive user input, other elements or input devices may be included in system 100 without departing from the scope of this disclosure. For example, system 100 may include directional input keys, a mouse pad, or a scroll wheel configured for navigating a GUI displayed on display 120. In some embodiments, system 100 is configured to receive user input from sound, which is detected by an audio input (e.g., one or more microphones) and processed by one or more processors (e.g., speech-to-text conversion) into a language form (e.g., command text, command code) that system 100 can recognize as an input command, such as a user's voice command, which is detected by one or more microphones (e.g., located inside, outside, and / or in any arrangement of the outer housing of system 100) and converted by one or more processors into command text that system 100 can recognize as an input command. In some embodiments, system 100 is configured to receive input from a user's visual motion (e.g., hand movement or gesture, object in a swipe motion), which is detected by a motion sensor (e.g., one or more cameras) and processed by one or more processors (e.g., action-to-text conversion) into a linguistic form (e.g., command text, command code), such as a user's hand gesture (e.g., hand in a swipe motion), which is detected by one or more cameras (e.g., located in any arrangement inside, outside, and / or part of the outer housing of system 100) and converted by one or more processors into command text that system 100 can recognize as an input command. Alternatively or in addition, system 100 may be configured to receive input other than user input, such as input from one or more sensors implemented for system 100. Non-limiting examples of various sensors that can be implemented (e.g., in a processing chamber) include: one or more optical sensors configured to measure light intensity at various locations within the processing chamber and / or incident on various locations of one or more biological fluids; one or more airflow sensors; one or more thermal sensors for measuring the temperature of the processing chamber and / or the temperature of one or more biological fluids; one or more sensors (e.g., pressure sensors, optical retroreflectance sensors, optical transmission sensors, tag readers, scanners, barcode scanners, RFID sensors, etc.) for detecting the presence and / or type of one or more biological fluids; one or more sensors (e.g., optical sensors, spectral sensors) for detecting properties (e.g., transmittance) of the biological fluids; one or more sensors (e.g., fluorescence spectroscopy) for detecting photochemical compounds in the biological fluids; and one or more sensors (e.g., ultrasonic sensors) positioned to detect the fluid depth of a portion (e.g., various portions) of one or more biological fluids.

[0052] In some embodiments, system 100 may be configured to receive input from one or more scanners implemented for system 100. In some embodiments, scanner 130 is configured to acquire information about the biofluid. In some examples, scanner 130 may be configured to acquire identification information associated with the biofluid to be processed. For example, the biofluid may be stored in a container (e.g., a blood-compatible bag, a processing bag) (not shown), and the container or other containers in a multi-container assembly (e.g., a disposable fluid processing kit) may include labels or markings or designated areas containing some form of identification information, such as visual forms (e.g., barcodes, QR codes, etc.) and / or transmissible forms (e.g., electronic identifiers, radio frequency identification (RFID)). In some embodiments, the identification information may represent information about the biofluid product, such as biological or other parameters (e.g., donation ID, product code, kit code, batch number, type of biofluid, volume of biofluid, content of biofluid, such as platelet count or concentration) and processing parameters. In some embodiments, biological or other parameters (optionally combined with input from one or more sensors and / or user input) may determine the processing parameters. In some examples, multiple sets of identification information can be obtained. For example, multiple sets of identification information may be located on one or more corresponding containers associated with the biological fluid (e.g., a portion of a multi-container assembly containing the biological fluid or containing the biological fluid), and multiple sets of identification information may be obtained from the corresponding containers by scanner 130. In some implementations, the scanner may be a multi-scan scanner (e.g., a camera with multi-scan capability, a camera cooperating with circuitry (e.g., hardware and / or software) with multi-scan processing capability, a handheld scanner with multi-scan capability, a handheld scanner cooperating with circuitry (e.g., hardware and / or software) with multi-scan processing capability, a tag reader with multi-scan capability, a tag reader cooperating with circuitry (e.g., hardware and / or software) with multi-scan processing capability), which is configured to sequentially or substantially simultaneously capture (e.g., acquire) multiple sets of identification information (e.g., multiple barcodes, multiple QR codes, multiple tags, different strings or arrangements of alphanumeric text and / or symbols, optical character recognition, image recognition, etc.) located on one or more containers, for example, capturing multiple sets of identification information in a “batch” mode (e.g., responding to a single user input or a single device input that commands, triggers, or otherwise initiates a multi-scan operation to acquire multiple sets of identification information).A single multi-scan operation can sequentially or substantially simultaneously (e.g., concurrently) capture multiple sets of identification information. For example, in a single operation, a camera may capture one or more images of one or more labels displaying multiple parameters of a biological product, such as donation ID, product code, kit code, batch number, type of biological fluid, volume of biological fluid, and content of biological fluid; in a single operation, the multi-scanner may perform one or more scans on one or more labels displaying the aforementioned multiple parameters. In some embodiments, the multi-scanner or system 100 is configured to recognize (and / or convert into another form recognized by the multi-scanner or system 100) the multiple sets of identification information captured in the multi-scan operation (e.g., recognizing (and / or decrypting) barcodes, QR codes, alphanumeric text and / or symbols, images). After capturing multiple sets of identification information (e.g., in captured images, in performed scans), the multiscanner can transmit or transfer them to system 100 in a recognized (and / or converted) form (e.g., in a language form that system 100 is already able to recognize, such as as parametric data) or an unrecognized form (e.g., captured images, performed scans) (e.g., via wired or wireless connections). If in an unrecognized form, system 100 can process the captured multiple sets of identification information into a recognized form. When displaying a GUI of the processing chamber associated with the biological fluid to be processed, system 100 can assign the multiple sets of identification information to corresponding fields in the GUI of display 120 (e.g., auto-fill information fields). Thus, multiscan operations can input all or most of the parametric data of the biological fluid into multiple specific data fields via a convenient, efficient, and time-saving auto-fill technique. For example, for multiscan operations, the user does not need to perform multiple scans in any particular order to capture multiple sets of identification information that can be presented in a specific order (e.g., it is not necessary to scan each label on the container in the visual order of the specific data fields presented to the user on the GUI).

[0053] In some embodiments, scanner 130 is integrated or embedded in a fixed location within system 100 (e.g., within the housing of system 100). In some embodiments, identification information can enter the field of view of scanner 130, and scanner 130 can acquire the identification information when the information is in the field of view. For example, a user can hold a biofluid processing container (e.g., a bag) with the barcode facing scanner 130, and scanner 130 can capture, scan, or read the barcode; based on the acquired barcode, system 100 can determine information about the biofluid product. In some embodiments, identification information can enter the detection range of scanner 130, and scanner 130 can acquire the identification information when the information is in the detection range. For example, a user can hold a biofluid processing bag with an RFID tag near scanner 130, and scanner 130 can detect the RFID tag; based on the information obtained from the detected RFID tag, system 100 can determine information about the biofluid product.

[0054] Although Figure 1 Scanner 130 is shown as being located outside system 100, but it can be located at different locations within system 100. In some embodiments, scanner 130 is located inside system 100. For example, scanner 130 may be located on top of the processing chamber of system 100 or at an opening in the processing chamber. After the biofluid is placed on the platform and / or in the chamber, scanner 130 can acquire information related to the biofluid.

[0055] In some examples, scanner 130 may be included in a device coupled to system 100. For example, scanner 130 may be included in a handheld scanner (e.g., a barcode scanner, QR code scanner) coupled to system 100. In some examples, the handheld scanner is coupled to system 100 via a wired connection. In some examples, the handheld scanner is coupled to system 100 via a wireless connection.

[0056] Although Figure 1 A scanner 130 is shown, but system 100 may include more than one scanner 130. For example, system 100 may include multiple processing chambers, and each processing chamber may have a corresponding scanner (e.g., an internal scanner). As another example, system 100 may include multiple platforms, and each platform may have a corresponding scanner (e.g., an external scanner) located near or at an opening of the respective platform. As the platform moves through the opening, a container containing biological fluid (e.g., a processing bag) may pass through the field of view of the corresponding scanner, and the corresponding scanner may obtain visual information about the biological fluid associated on the container or associated container of a multi-container assembly.

[0057] In some embodiments, platform 140 (e.g., tray, recess, plate, table) is configured to carry biological fluid during treatment (e.g., in a container containing biological fluid). In some embodiments, the platform is movable between the interior and exterior of the treatment chamber (e.g., slidably movable, configured to translate from the interior to the exterior of the treatment chamber) (e.g., partially removed from the treatment chamber). In some embodiments, system 100 also includes a first panel 180 movable between a closed position and an open position, wherein the first panel 180 covers a first opening to the first treatment chamber in the closed position and exposes the first opening to the first treatment chamber in the open position. In some embodiments, the first panel may have a handle (e.g., a protruding handle, a recessed handle). The handle allows a user to manually open or close the first panel to load or unload biological fluid into or from the chamber. In some examples, the exterior of the first panel may include an opening or notch serving as a recessed handle. In some examples, the handle may be attached to the exterior of the first panel. In some embodiments, the first panel is attached to, integrated with, or formed together with the platform 140 (e.g., in a drawer configuration). In some embodiments, the first panel 180 is a separate structure from the platform 140 (e.g., a separate hinged door that covers and exposes a first opening to the first processing chamber), and the platform 140 can slide into and out of the first processing chamber separately from the first panel 180.

[0058] In some examples, the platform and / or the first panel can be locked to remain in the closed position during processing. System 100 can prevent a user from prematurely accessing the contents of platform 140 (e.g., approaching the first processing chamber) during processing by locking the first panel to remain in the closed position. In some embodiments, the first panel can be locked by a pin (e.g., a solenoid and pin) or a magnetic locking mechanism. System 100 can allow a user to access the contents of platform 140 before and after processing (e.g., loading biofluid onto platform 140, unloading biofluid from platform 140) or after input (e.g., input on a GUI, input to open a latch, input to a push-button switch).

[0059] In some implementations, the exterior of the first panel is substantially smooth, making the exterior surface continuous. For example, the surface of the first panel on the exterior of system 100 (e.g., the outer housing) may be flat. As another example, the surface of the first panel on the exterior of system 100 may be continuously smooth; that is, the surface of the first panel on the exterior of system 100 may not have any openings, notches, gaps, etc., or any openings, notches, gaps, etc. may be small enough to prevent a user from pulling the first panel with their fingers. Such sufficiently small openings, notches, gaps, etc., can provide air ventilation in the first panel. As yet another example, the entire exterior (e.g., surface) of the first panel lacks any handles, protrusions, etc. As another example, when in the closed position, the edge of the first panel may be flush or substantially flush with adjacent structures (e.g., adjacent panels, adjacent frames of the outer housing, etc.), wherein any openings, notches, gaps, etc. between the edge of the first panel and the adjacent structure are small enough to prevent a user from pulling the first panel with their fingers (e.g., preventing frictional pulling on the side of the edge of the first panel, preventing hook pulling on the rear side of the edge of the first panel), such as... Figure 1 As shown. In some embodiments, the continuous external surface prevents the user from prematurely opening the first panel by manual operation (e.g., when handling biological fluids) or unintentionally damaging the system by forcefully pulling the handle. If the first panel is opened prematurely, the biological fluid being handled may be damaged, or the biological fluid may not be adequately handled. If the user forcefully pulls the handle of the locked first panel, the handle may be damaged, the moving mechanism (e.g., track, rail) may be damaged, or the lock may be damaged.

[0060] like Figure 1 As shown, the structure of platform 150 is a mirror image of the structure of platform 140, symmetrical about a vertical axis. In some embodiments, platform 150 is substantially similar to platform 140 in size, shape, or orientation. As shown, platforms 140 and 150 are arranged horizontally such that the first biofluid and the second biofluid lie in the same plane when positioned on the first and second platforms, respectively. As described above, since the first panel 180 can be associated with platform 140, the second panel 190 can be associated with platform 150. The above-described teachings of the first panel 180 can also be applied to the second panel 190.

[0061] Although the two platforms are Figure 1While shown as part of system 100, system 100 may include one or more platforms, said more than two platforms being substantially similar to platform 140 or platform 150, without departing from the scope of this disclosure. Typically, the number of platforms and processing chambers shown associated with systems 100-700 is exemplary; embodiments of systems 100-700 may include different numbers and combinations of platforms, processing chambers, and their associated elements (e.g., scanners, optical arrays, compartments) without departing from the scope of this disclosure. For example, in some embodiments, the system may include only one chamber with only one platform. In some embodiments, the system may include only one chamber with two or more platforms. In some embodiments, the system may include two chambers, each with only one platform. In some embodiments, the system may include two chambers, each with two or more platforms.

[0062] In some embodiments, the platform includes a first compartment and a second compartment separate from the first compartment. In some embodiments, the first compartment is configured to hold a container (e.g., a container of multiple container assemblies) containing biological fluid at a location used for irradiation. In some embodiments, the second compartment is configured to hold a container (e.g., a container of multiple container assemblies) not containing biological fluid at a location not used for irradiation. In some embodiments, the platform is configured to hold at least a first container having a first biological fluid and a second container having a second biological fluid, respectively. In some embodiments, the platform is transparent to light with wavelengths within 100 nm (e.g., 75 nm, 50 nm, 40 nm, 30 nm, 20 nm) of the peak wavelength of the light used for irradiation (e.g., substantially transparent, >95% transparent, >90% transparent, >80% transparent, >80% transparent). In some embodiments, the platform is transparent to ultraviolet light (e.g., UV-A, UV-B, and / or UV-C) (e.g., substantially transparent, >95% transparent, >90% transparent, >80% transparent, >80% transparent).

[0063] Figure 2A An exemplary system 200 for processing biological fluids is shown. In some embodiments, system 200 is substantially similar to Figure 1 The system 100 shown. Power switch 210 may correspond to power switch 110. Display 220 may correspond to display 120. Platforms 240 and 250 may correspond to platforms 140 and 150, respectively. Panels 280 and 290 may correspond to panels 180 and 190, respectively.

[0064] In some embodiments, system 200 includes an external scanner 230. In some embodiments, the external scanner 230 is in addition to a scanner integrated or embedded in a fixed location within system 200. As shown, the external scanner 230 is external to a housing that houses other components and can be operatively coupled to the processor of system 200. In some embodiments, the external scanner 230 is a handheld scanner. Although the external scanner 230 is in... Figure 2A The device is shown to have wireless connectivity, but the external scanner 230 can be operatively coupled using a wired connection.

[0065] like Figure 2A As shown, and in Figure 1 Platforms 140 and 150 are in the closed position, while platforms 240 and 250 are in the open position in the drawer configuration. Although in Figure 2A The two platforms 240 and 250 are shown as being opened in a drawer configuration, but it is also possible to open one platform at a time in a drawer configuration (e.g., while the other platform remains closed).

[0066] In some embodiments, the first panel 280 and the second panel 290 associated with platforms 240 and 250 do not have any handles. In some embodiments, in the closed position, the panels can be opened by applying a force opposite to the opening direction (e.g., pushing the outside of the panel to engage a push latch that releases the panel to open). In some embodiments, in the closed position, the panels can be opened using mechanical components (e.g., a motor, a servo mechanism) to actuate the panels (e.g., as a hinged door, as part of the platform in a drawer configuration). In some embodiments, the system may allow a user to access the contents of the platform by opening the panel (e.g., via a spring mechanism) to allow the user to further manually slide the platform out. For example, based on the determination of the start or completion of a processing procedure, the system may mechanically open one or more panels corresponding to a processing procedure for loading or unloading one or more biofluid containers (e.g., processing bags).

[0067] In some implementations, the platform includes a compartment 260 that is substantially similar to the compartment described herein. Although Figure 2A A platform with a visible compartment is shown (e.g., for a platform in the open position in a drawer configuration), but each platform in system 200 may include any number of compartments without departing from the scope of this application.

[0068] In some implementations, the panel may include a handle. Figure 2B A panel associated with platform 250 is shown, which has a protruding handle 270 physically attached to the panel. Figure 2CA panel associated with platform 250 is shown, having a recessed handle 270 as part of the panel. In some embodiments, without the handle or with the absence of a handle, the panel may be flush or substantially flush with adjacent structures (e.g., adjacent panels, adjacent frames of the outer housing, etc.), such as Figure 2A-2C As shown.

[0069] Figure 3A An exemplary system 300 for processing biological fluids is shown. In some embodiments, system 300 is substantially similar to system 100, except that the processing chamber and platform are arranged vertically. Power switch 310 may correspond to power switch 110. Display 320 may correspond to display 120. Scanner 330 may correspond to scanner 130. In contrast to system 100, in which platforms 140 and 150 are arranged horizontally, platforms 340 and 350 are arranged vertically such that the first and second biological fluids are located in parallel planes when positioned on the first and second platforms, respectively. Similarly, in contrast to system 300, in which panels 180 and 190 are arranged horizontally, panels 380 and 390 are arranged vertically.

[0070] In some implementations, system 300 may include air ventilation. Figure 3BPanels 380 and 390 are shown, each having an air vent 385 and 395, respectively. The air vents 385 and 395 may provide one or more air inlets (e.g., air intakes) through which air is drawn into system 300, for example, to provide cooling or heat dissipation or other temperature control functions. The air vents 385 and 395 may provide one or more air outlets through which air is exhausted from system 300, for example, to provide cooling or heat dissipation or other temperature control functions. Air may be drawn into and / or exhausted from system 300 by, for example, the operation of one or more fans within system 300. The air vents 385 and 395 are shown as, but not limited to, ventilation openings (e.g., circular ventilation openings) and may be implemented in any variation or combination of variations, such as horizontal vents, vertical vents, grilles, elliptical ventilation openings, rectangular or square ventilation openings, polygonal ventilation openings, or any combination thereof. The air vents 385 and 395 are shown as, but not limited to, occupying a large portion of the panel area, and can be implemented in any variation or combination of variations, such as occupying the entire panel area, occupying a portion of the panel area, different horizontal ventilation bands, different vertical ventilation bands, circular or elliptical ventilation bands, rectangular or square ventilation bands, polygonal ventilation bands, or any combination thereof. Such air vents 385 and 395 are not limited to the panel's location but can be located in other locations (e.g., as a replacement or supplement to the panel), such as as part of the housing, in front of or near the housing (e.g., above, below, or near the panel). In some embodiments, in the absence of air ventilation or in the absence of air ventilation, the panel can be flush or substantially flush with adjacent structures (e.g., adjacent panels, adjacent frames of the outer housing, etc.), such as... Figures 3A-3B As shown.

[0071] In some implementations, system 300 may include one or more access panels (e.g., front access panel, side access panel, top access panel) through which maintenance or repair personnel can access internal components or structures of system 300 and then perform maintenance or repair on the internal components or structures of the system. Figure 3B An exemplary side access panel 302 of system 300 located on the side of the outer housing is shown. The side access panel 302 can open in any manner, such as with a vertical hinge (e.g., located at the rear vertical edge of the side access panel 302), a horizontal hinge (e.g., located at the top or bottom of the side access panel), fasteners (e.g., screws holding the side access panel in place), etc. The side access panel 302 is shown as, but is not limited to, surrounding... Figure 3BThe area between the two horizontal lines shown can be implemented in any variation or combination of variations, such as surrounding the entire side of the outer housing, surrounding a portion of the side of the outer housing, surrounding multiple sides near the panel (e.g., one for each processing chamber), etc.

[0072] Figure 4A An exemplary system 400 for processing biological fluids is shown. In some embodiments, system 400 is substantially similar to system 300, as shown in FIG3. Power switch 410 may correspond to power switch 310. Display 420 may correspond to display 320. Scanner 430 may correspond to scanner 330. Platforms 440 and 450 may correspond to platforms 340 and 350, respectively. Panels 480 and 490 may correspond to panels 380 and 390, respectively.

[0073] As shown in the figure, opposite to the closed position of platform 340 in Figure 3, platform 440 is in... Figure 4A In the drawer configuration, it is in the open position. Although in Figure 4A The image shows one platform of the drawer configuration open, but both platforms in the drawer configuration can be opened simultaneously.

[0074] In some embodiments, the first panel 480 and the second panel 490 associated with platforms 440 and 450 do not have any handles. In some embodiments, in the closed position, the panels can be opened by applying a force opposite to the opening direction (e.g., pushing the outside of the panel to engage a push latch that releases the panel to open). In some embodiments, in the closed position, the panels can be opened using mechanical components (e.g., a motor, a servo mechanism) to actuate the panels (e.g., as a hinged door, as part of the platform in a drawer configuration). In some embodiments, the system may allow a user to access the contents of the platform by opening the panel (e.g., via a spring mechanism) to allow the user to further manually slide the platform out. For example, based on the determination of the start or completion of a processing procedure, the system may mechanically open one or more panels corresponding to a processing procedure for loading or unloading one or more biological fluid containers (e.g., processing bags).

[0075] In some implementations, the platform includes compartments 460A and 460B that are substantially similar to the compartments described herein. Although Figure 4A A platform with two compartments is shown, but each platform in system 400 may include any number of compartments without departing from the scope of this application.

[0076] In some implementations, the panel may include a handle. Figure 4B A panel associated with platform 440 is shown, which has a protruding handle 470 physically attached to the panel. Figure 4CA panel associated with platform 440 is shown, which has a recessed handle 470 as part of the panel. In some embodiments, without the handle or in the absence of a handle, the panel may be flush or substantially flush with adjacent structures (e.g., adjacent panels, adjacent frames of the outer housing, etc.), such as Figures 4A-4C As shown.

[0077] In some embodiments, system 400 may provide an agitation function for agitating the biological fluid during treatment by irradiation. Agitation can facilitate treatment, for example, by providing mixing of compounds in the biological fluid (e.g., photochemical compounds, pathogen-inactivating compounds), or by maintaining the components of the biological fluid (e.g., platelets, cells) in suspension. System 400 may be via... Figure 4A-4I The structural elements provide an agitation function. For example, the first platform 440 may include an outer region and an inner region. The outer region may include a first panel 480 movable between a closed position and an open position, for example, when the outer region is slidably moved into and out of the first (top) processing chamber via an outer guide rail or track 462. In the closed position, the first panel 480 covers a first opening leading to the first processing chamber. In the open position, the first panel 480 exposes the first opening leading to the first processing chamber. The outer region may also include a first support structure that structurally supports the inner region; for example, the outer region may include an inner guide rail or track 464 that structurally supports the compartments 460A and 460B of the inner region. Figure 4A In this embodiment, protruding structures in the sidewalls of compartments 460A and 460B can engage with internal guide rails. In some embodiments, the edges of compartments 460A and 460B form lips on the internal and external guide rails. The internal region can be configured to move to agitate the first biofluid during a period when the external region is in a fixed position. For example, when the system 400 irradiates the first biofluid in compartments 460A and / or 460B, the external region including the first panel 480 can be fixed in a closed position, but the internal region can move to agitate the first biofluid. Both the first panel 480 and the external guide rail 462 can be part of the structure of the external region, but the first panel 480 may not be attached to compartments 460A and 460B. When the first panel 480 is part of the structure of the external region of the first platform 440, the first panel 480 can be integrated with the external region structure (e.g., in an integrally formed piece) or attached to the external region structure (e.g., as a separately formed piece).

[0078] Movement of the internal region can be based on motion generated by one or more motors or servo mechanisms. For example, the external region may include one or more electric motors configured to generate such motion. The internal region may be configured to agitate a first biofluid in compartments 460A and / or 460B based on the generated motion. System 400 may be configured to control (e.g., adjustably control) one or more aspects of the movement of the internal region, such as offset (i.e., the stroke length of reciprocating (e.g., linear, forward, and backward, etc.) motion during agitation), velocity, acceleration, and deceleration. Movement of the internal region may be forward and backward (e.g., along an internal guideway of the external region), or may include movement in other directions. In some embodiments, system 400 may be configured to control the movement of the internal region to change its position for calibration purposes (e.g., calibration of a light source array).

[0079] One or more motors or servo mechanisms may be located in front of or behind the location where the first biofluid will be carried by the first platform 440. For example, an electric motor may be located in front of compartment 460B between the first panel 480 and compartment 460B. As another example, an electric motor may be located behind compartment 460A within system 400. As yet another example, an electric motor may be located in front of compartment 460B between the first panel 480 and compartment 460B, while another electric motor may be located behind compartment 460A within system 400.

[0080] Figure 4D-4F Another embodiment is shown in which one or more motors or servo mechanisms may be located in front of or behind the location where the first biofluid will be carried by the first platform 440. In this embodiment, the outer region of the first platform 440 includes a first support structure that structurally supports the inner region via internal guides or tracks 464 that engage with the inner region (e.g., the edge of a compartment in the inner region), thereby providing structural support above, below, and / or near the edge. In this embodiment, one or more motors or servo mechanisms 466, 468 may be located in front of the compartment (e.g., on the back of the first panel 480, etc.) and / or behind the compartment (e.g., in the outer region of the first platform 440 at a location behind compartment 460A). Figure 4D-4F This embodiment is shown, in which the internal region is in different positions during agitation or calibration. Figure 4D The position of the internal region is shown when it is positioned near or adjacent to the first panel 480 during agitation. Figure 4E This shows the position of the inner region when it has moved backward along the inner guide rail away from the first panel 480 to the middle position during agitation. Figure 4FThis illustrates the position of the inner region during agitation when it has moved further rearward along the inner guide rail away from the first panel 480 to its final position. During agitation or calibration, the outer region may be held in place, but the inner region may move forward and backward. Figure 4D-4F The location shown.

[0081] One or more motors or servo mechanisms may be located on the right or left side of the first biofluid to be carried by the first platform 440. For example, an electric motor may be located on the right side of compartment 460A (or 460B) between the right outer guide rail and compartment 460A (or 460B). As another example, an electric motor may be located on the left side of compartment 460A (or 460B) between the left outer guide rail and compartment 460A (or 460B). As yet another example, an electric motor may be located on the right side of compartment 460A (or 460B) between the right outer guide rail and compartment 460A (or 460B), while another electric motor may be located on the left side of compartment 460A (or 460B) between the left outer guide rail and compartment 460A (or 460B).

[0082] Figure 4G-4I Another embodiment is shown in which one or more motors or servo mechanisms 465 may be located to the left of the position where the first biofluid will be carried by the first platform 440. In this embodiment, the outer region of the first platform 440 includes a first support structure that structurally supports the inner region via internal guides or tracks 464 that engage with the inner region (e.g., the edge of a compartment of the inner region), thereby providing structural support above, below, and / or near the edge. To the left of the compartment of the inner region, the outer region includes a relatively wide structure that accommodates one or more motors or servo mechanisms. Figure 4G-4I This embodiment is shown, in which the internal region is in different positions during agitation or calibration. Figure 4G The position of the internal region is shown when it is positioned near or adjacent to the first panel 480 during agitation. Figure 4H This shows the position of the inner region when it has moved backward along the inner guide rail away from the first panel 480 to the middle position during agitation. Figure 4I This illustrates the position of the inner region during agitation when it has moved further rearward along the inner guide rail away from the first panel 480 to its final position. During agitation or calibration, the outer region may remain fixed in place, but the inner region may move forward and backward. Figure 4G-4I The location shown.

[0083] In some embodiments, system 400 may provide an agitation function via a second platform 450 for agitating the biological fluid during irradiation treatment. The second platform 450 may implement teachings similar to those of the first platform 440 described above. For example, the second platform 450 may include an outer region and an inner region. The outer region may include a second panel 490 movable between a closed position and an open position, for example, when the outer region is slidably moved into and out of a second (bottom) treatment chamber via an outer guide rail. In the closed position, the second panel 490 covers a second opening to system 400, i.e., an opening to the second treatment chamber. In the open position, the second panel 490 exposes the second opening, i.e., the opening to the second treatment chamber. The outer region may also include a second support structure that structurally supports the inner region; for example, the outer region may include internal guide rails or tracks that structurally support the inner region. The inner region may be configured to move during periods when the outer region is in a fixed position to agitate the second biological fluid. For example, when the system 400 irradiates a second biofluid in a compartment of the inner region, the outer region including the second panel 490 can be fixed in a closed position, but the inner region can move to agitate the second biofluid. Both the second panel 490 and the outer rails of the second platform 450 can be part of the structure of the outer region of the second platform 450, but the second panel 490 may not be attached to the compartment of the inner region. When the second panel 490 is part of the structure of the outer region of the second platform 450, the second panel 490 can be integrated with the outer region structure (e.g., in an integrally formed piece) or attached to the outer region structure (e.g., as a separately formed piece). The outer region of the second platform 450 may include one or more electric motors or servo mechanisms configured to generate motion and thereby provide movement of the inner region. In some embodiments, the system 400 may be configured to control the movement of the inner region of the second platform 450 to change its position for calibration purposes (e.g., calibration of a light source array).

[0084] Figure 4JA side view of the interior of system 400 is shown. At the top, this side view shows the upper level, including a display 420 (e.g., a touchscreen) and control circuitry and / or a computer system. Moving downwards, a first light source array 406 is positioned above and facing the first platform 440, wherein the light sources are oriented to emit downwards within the first processing chamber to illuminate a first biofluid positioned on the first platform 440. Moving downwards, a second light source array 408 is positioned below and facing the first platform 440, wherein the light sources are oriented to emit upwards within the first processing chamber to illuminate the first biofluid positioned on the first platform 440. Moving downwards, a third light source array 416 is positioned above and facing the second platform 450, wherein the light sources are oriented to emit downwards within the second processing chamber to illuminate a second biofluid positioned on the second platform 450. At the bottom, a fourth light source array 418 is positioned below and facing the second platform 450, wherein the light sources are oriented to emit upwards within the second processing chamber to illuminate a second biofluid positioned on the second platform 450. In some embodiments where irradiation originates from below the platform, the bottom of the platform (e.g., the bottom of its compartment for the biofluid) may be transparent to the irradiation, allowing the irradiation to reach the biofluid on the platform. In some embodiments, the platform is transparent to light having wavelengths within 100 nm (e.g., 75 nm, 50 nm, 40 nm, 30 nm, 20 nm) of the peak wavelength of the light used for irradiation (e.g., completely or partially transparent, at least 85% transparent, sufficiently transparent to process the biofluid, sufficiently transparent to achieve the desired treatment result). In some embodiments, the platform is transparent to ultraviolet light (e.g., UV-A, UV-B, and / or UV-C) (e.g., completely or partially transparent, at least 85% transparent, sufficiently transparent to process the biofluid, sufficiently transparent to achieve the desired treatment result).

[0085] Electrical wiring for powering and / or controlling electric motors or servo mechanisms can be located inside or along the external area, for example, inside the internal guide rails or along the (internal or external) sidewalls, top surface, or bottom surface of the external area. This location of electrical wiring for the exterior of the platform compartment (e.g., outside the internal area of ​​the platform) avoids obstructing illumination from a light source array that projects light onto the compartment from above or below.

[0086] In some implementations, one or more platforms of system 400 may each include an internal region component 461, which provides one or more removable internal region portions, such as Figure 4KAs shown. The internal region assembly 461 may include one or more removable portions 463 (e.g., in the form of a tray, recess, plate, table, etc.) and a support 467 portion of the internal region for receiving one or more removable portions 463. The removable portion 463 may include a rear compartment 460A having a compartment floor 469 made of a material that is completely or partially transparent (e.g., at least 85% transparent, sufficiently transparent to handle biological fluids, sufficiently transparent to achieve the desired treatment outcome) to light emitted by a light source array as provided herein (e.g., ultraviolet light, UV-A, UV-B and / or UV-C) (e.g., the peak wavelength of the light). (For example, Made of G-UVT). The compartment floor 469 itself is removable from the rear compartment 460A for replacement and / or cleaning. The rear compartment 469 can be configured to carry one or more containers containing one or more biological fluids at one or more locations for irradiation from above and / or below the containers. The front compartment 460B can be configured to carry one or more other containers but not in the irradiation location. The containers for the front compartment and the containers for the rear compartment can both be part of a multi-container assembly. A support 467 can align and hold one or more removable portions 463 in a stable position and desired orientation. The support 467 can be supported by an external area of ​​the platform, such as mounted to or within an internal guide rail or track 464 included in the external area of ​​the platform. One or more motors or servo mechanisms 468 can be mounted to or on the platform (e.g., an external area of ​​the platform) and located behind the rear compartment. One or more motors or servo mechanisms 468 may be physically coupled to a support 467 and may move the support 467 forward and backward (e.g., along an internal guide rail or track 464 along an outer region of the platform) to agitate the biofluid carried on the platform (e.g., biofluid in a container). The one or more motors or servo mechanisms 468 may be part of any suitable agitation design (e.g., a lead screw design in which one or more motors or servo mechanisms move a lead screw attached to the support, or a belt-driven design in which one or more motors or servo mechanisms move one or more belts that cause one or more gears (e.g., gears with teeth) to rotate, and the one or more gears mesh and move one or more tracks attached to the support), and may be operated based on control signals from electrical wiring electrically connected to control circuitry. In some embodiments, the agitation speed may be adjustable (e.g., adjusted to have different speeds between different treatments, adjusted to have different speeds during a single treatment, adjusted based on a predetermined speed schedule, or dynamically adjusted in real time based on real-time user input). Such control circuitry may control one or more motors or servo mechanisms 468 based on a control program implemented as software and / or hardware control circuitry. The external guide rail or track 462 may be part of the structure of the external area of ​​the platform, and the external area may be slidably moved into and out of the processing chamber of the platform via the external guide rail or track 462.Sensors for the platform may include, for example: a platform position / locking / latch sensor for sensing whether the platform is in a closed position and / or locked / latched; a bracket position sensor for sensing the position of the bracket along the internal guide rail or track 464; a removable internal area portion sensor for sensing whether one or more removable internal area portions are in the bracket; a temperature sensor for sensing the temperature of the platform or the biofluid carried on the platform at one or more locations (e.g., the position of the rear compartment 460A, the position of the front compartment 460B, the position of one or more motors or servo mechanisms 468); and a sensor for sensing the presence and / or weight of the biofluid carried on the platform (e.g., biofluid in a container), etc.

[0087] Figure 4L It shows Figure 4K The diagram shows a rear perspective view of the platform. In this rear perspective view, the rear of the platform's front panel is shown. Within the front panel, the front panel may include a filter compartment 472, which may include an air filter 474 for filtering incoming air. The filter compartment 472 may be accessible, such that the air filter 474 may be replaceable and / or cleanable. Figure 4L One or more electric motors or servo mechanisms 468 are shown mounted on or on a platform (e.g., an external area of ​​the platform) and located behind the rear compartment 460A. The one or more motors or servo mechanisms 468 may (e.g., via lead screws, belts and gears, and rails) be physically coupled to a bracket 467 in the internal area and may move the bracket 467 forward and backward (e.g., along an internal guide rail or track 464 along the external area of ​​the platform) to agitate the biological fluid when in the rear compartment 460A. Figure 4L A platform locking assembly 476 is shown, which is physically coupled to an external area of ​​the platform. When the platform locking assembly is in the unlocked state, the front panel can be opened, and the external area can be slidably moved into and out of the processing chamber via an external guide rail or track 462. When the platform locking assembly is in the locked state, it engages a locking mechanism to prevent the front panel from opening and the external area from moving. In some embodiments, the locking mechanism may be: motor-based (e.g., locking a motor / servo mechanism physically coupled to the external area or front panel so that the external area cannot move), latch-based (e.g., moving a rigid member (e.g., a latch, pin, or hook) to engage a receiving structure (e.g., a slot, hole, or groove) physically coupled to the external area or front panel so that the external area cannot move), magnetic-based (e.g., engaging an electromagnet to magnetically hold the structure of the external area of ​​the platform and the fixed structure of the system 100 together, wherein the electromagnet may be located on or in the structure of the external area of ​​the platform, the fixed structure of the system 100, or both), etc. Figure 4LThe side of a platform supported by a fixed structure (e.g., the side of the outer region of the platform) is shown, which can support the outer guide rail or track 462 of the outer region of the platform.

[0088] Despite Figure 1-4L The system is illustrated as having platforms arranged horizontally or vertically, but the platform arrangement shown is not limiting. For example, the platforms of a four-processing-room and / or four-platform system can be arranged in a 2x2 array.

[0089] exist Figure 1-4L Above and in Figures 9A-9F The following sections typically cover teaching content regarding system form factors, user interface elements, housing configuration, and processing chamber configuration. Figure 1-4L and Figures 9A-9F All systems within it can process biological fluids through irradiation. For Figure 1-4L and Figures 9A-9F Further details about the system's illumination characteristics (e.g., light source array, light source channels, peak wavelength, light intensity, light type, spectral bandwidth) are provided through... Figure 5-8 And its corresponding public content is provided.

[0090] Figure 5 This is a perspective view of an exemplary system 500 for processing biological fluids. In some embodiments, system 500 is substantially similar to... Figure 1 The system 100 shown. An exemplary system 500 for processing biological fluids includes a first processing chamber 502 and a second processing chamber 504 for receiving one or more biological fluids 510, and a light source array 506 positioned to irradiate the one or more biological fluids 510 (e.g., positioned below and irradiating the biological fluids upwards). In some embodiments, the light source array 506 may include a single light source in chambers 502 and 504 positioned to irradiate the one or more biological fluids 510. References below Figure 7 In other embodiments described, multiple light source arrays can be used to irradiate one or more biological fluids positioned in chambers 502 and 504 in various embodiments (e.g., two light source arrays positioned vertically (up and down relative to each other)). Figure 7 Each light source array is used to irradiate one or more biological fluids. As described herein, a "light source array" refers to one or more light sources disposed on any two-dimensional or three-dimensional surface (e.g., continuous surface, discontinuous surface).

[0091] One or more light source channels may be included in the light source array of this disclosure. In some embodiments, one or more light source channels 508 are included in light source array 506. While a particular light source is shown as belonging to a particular light source channel, it should be understood that different combinations of light sources can form different light source channels. Each light source channel 508 may be a group of one or more light sources having substantially the same wavelength (e.g., peak wavelength, maximum peak wavelength). In an exemplary group, one light source may have a peak wavelength. In another exemplary group, two light sources may have the same peak wavelength as each other. In yet another exemplary group, each of the multiple light sources may have a different peak wavelength than each other. In yet another exemplary group, a first subgroup of one or more light sources may have a peak wavelength, and a second subgroup of one or more light sources may have different peak wavelengths. Within a light source channel having multiple light sources, all light sources may have a corresponding peak wavelength (e.g., maximum peak wavelength), and all peak wavelengths are within the wavelength range used for the light source channel (e.g., 1nm-20nm, 1nm-10nm range; e.g., 1nm, 2nm, 3nm, 4nm, 5nm or greater, greater than and / or less than a specific wavelength). For example, in some embodiments, within a light source channel having multiple light sources, all light sources can have peak wavelengths within the range set forth in this disclosure, such as about 315 nm to about 350 nm (e.g., about 315 nm to about 335 nm, about 330 nm to about 350 nm, about 340 nm to about 350 nm). In the light source channel, each light source can be any light source providing desired characteristics (e.g., peak wavelength, maximum peak wavelength, spectral bandwidth), including but not limited to solid-state lighting devices (SSLs), light-emitting diodes (LEDs), organic light-emitting diodes (OLEDs), polymer light-emitting diodes (PLEDs), and laser diodes. The light source channels of the light source array can be connected in series, in parallel, or a combination of series and parallel circuits. In a light source channel having multiple light sources, these light sources can be controlled together or separately.

[0092] Each light source channel can be adjusted or configured to emit light of different intensities (e.g., adjusting the light dose, adjusting the energy dose), at which light of one or more peak wavelengths is applied to one or more portions of the biological fluid. For example, each light source channel can emit light at a maximum intensity (e.g., 100%) or less than a maximum intensity (e.g., about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or less).

[0093] Each light source channel can emit various types of light. For example, each light source channel can emit ultraviolet light, ultraviolet A light, ultraviolet B light, ultraviolet C light, and / or visible light. Furthermore, each light source channel can emit light with various peak wavelengths. For example, the emitted peak wavelengths can be in the ultraviolet A spectrum (e.g., 315nm-400nm), ultraviolet B spectrum (e.g., 280nm-315nm), ultraviolet C spectrum (e.g., 100nm-280nm, 200nm-280nm, 240nm-280nm), or visible spectrum (e.g., 400nm-800nm). In some embodiments, the emitted peak wavelength may be between about 240 nm and about 250 nm, about 245 nm and about 255 nm, about 250 nm and about 260 nm, about 255 nm and about 265 nm, about 260 nm and about 270 nm, about 265 nm and about 275 nm, about 270 nm and about 280 nm, or about 275 nm and about 285 nm. In some embodiments, the emitted peak wavelength may be between about 280 nm and about 290 nm, about 285 nm and about 295 nm, about 290 nm and about 300 nm, about 300 nm and about 310 nm, about 305 nm and about 315 nm, or about 310 nm and about 320 nm. In some implementations, the emitted peak wavelength can be between approximately 315 nm and approximately 325 nm, between approximately 320 nm and approximately 330 nm, between approximately 325 nm and approximately 335 nm, between approximately 330 nm and approximately 340 nm, between approximately 335 nm and approximately 345 nm, between approximately 340 nm and approximately 350 nm, between approximately 345 nm and approximately 355 nm, between approximately 350 nm and approximately 360 nm, between approximately 355 nm and approximately 365 nm, between approximately 360 nm and approximately 370 nm, between approximately 365 nm and approximately 375 nm, between approximately 370 nm and approximately 380 nm, between approximately 375 nm and approximately 385 nm, between approximately 380 nm and approximately 390 nm, between approximately 385 nm and approximately 395 nm, and between approximately 390 nm and approximately 400 nm. In some implementations, the peak wavelength emitted may be approximately 240 nm, approximately 245 nm, approximately 250 nm, approximately 255 nm, approximately 260 nm, approximately 265 nm, approximately 270 nm, approximately 275 nm, approximately 280 nm, approximately 285 nm, approximately 290 nm, approximately 295 nm, approximately 300 nm, approximately 305 nm, approximately 310 nm, approximately 315 nm, approximately 320 nm, approximately 325 nm, approximately 330 nm, approximately 335 nm, approximately 340 nm, approximately 345 nm, approximately 350 nm, approximately 355 nm, approximately 360 nm, approximately 365 nm, approximately 370 nm, approximately 375 nm, approximately 380 nm, approximately 385 nm, approximately 390 nm, approximately 395 nm, or approximately 400 nm.In some embodiments, the emitted peak wavelength can be between about 255 nm and about 275 nm (e.g., between about 260 nm and about 270 nm, about 265 nm). In some embodiments, the emitted peak wavelength can be between about 275 nm and about 295 nm (e.g., between about 280 nm and about 290 nm, about 285 nm). In some embodiments, the emitted peak wavelength can be between about 300 nm and about 320 nm (e.g., between about 305 nm and about 315 nm, about 310 nm). In some embodiments, the emitted peak wavelength can be between about 315 nm and about 335 nm (e.g., between about 320 nm and about 330 nm, about 325 nm). In some embodiments, the emitted peak wavelength can be between about 330 nm and about 350 nm (e.g., between about 335 nm and about 345 nm, between about 340 nm and about 350 nm, about 340 nm, about 345 nm). In some embodiments, the emitted peak wavelength may be between about 355 nm and about 375 nm (e.g., between about 360 nm and about 370 nm, about 365 nm). In some embodiments, the emitted peak wavelength may be between about 375 nm and about 395 nm (e.g., between about 380 nm and about 390 nm, about 385 nm). In some embodiments, the emitted peak wavelength may be in: (1) the ultraviolet A spectrum (e.g., 315 nm–400 nm); and (2) the ultraviolet B spectrum (e.g., 280 nm–315 nm) or the ultraviolet C spectrum (e.g., 100 nm–280 nm, 200 nm–280 nm, 240 nm–280 nm). In some embodiments, the emitted peak wavelength is in the ultraviolet A spectrum between about 315 nm and about 350 nm (e.g., between about 320 nm and about 345 nm, between about 315 nm and about 335 nm, between about 330 nm and about 350 nm, between about 340 nm and about 350 nm).

[0094] In some embodiments, all light source channels of the light source array can emit light with approximately the same peak wavelength (e.g., the maximum peak wavelength) (e.g., within a difference of ±1 nm, ±2 nm, ±3 nm, ±4 nm, ±5 nm, ±6 nm, ±7 nm, ±8 nm, ±9 nm, ±10 nm). For example, in some embodiments, all light source channels of the light source array can emit light with peak wavelengths of 325 ±10 nm, 330 ±10 nm, 335 ±10 nm, 340 ±10 nm, 325 ±5 nm, 330 ±5 nm, 335 ±5 nm, 340 ±5 nm, 345 ±5 nm, 345 ±4 nm, 345 ±3 nm, or 345 ±2 nm. A light source channel can include multiple light sources having different peak wavelengths (e.g., measured peak wavelengths) within a varying range. In some embodiments, the average peak wavelength across multiple light sources in a single light source channel can be the same as the specific peak wavelength of a particular light source in that single light source channel. In other embodiments, the average peak wavelength across multiple light sources in a single light source channel may differ from all specific peak wavelengths of each light source in the single light source channel (e.g., greater than or less than about 1 nm, 2 nm, 3 nm, 4 nm, 5 nm, or greater). In some embodiments, some light source channels may emit light at a first peak wavelength, and other light source channels may emit light at a second peak wavelength. The first peak wavelength may differ from the second peak wavelength by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm or more. For example, in a non-limiting embodiment, the first light source channel may emit light having a peak wavelength in the ultraviolet A spectrum as described above (e.g., between about 315 nm and about 335 nm, between about 330 nm and about 350 nm, between about 340 nm and about 350 nm), and the second light source channel may emit light having a peak wavelength in the ultraviolet C spectrum as described above (e.g., between about 250 nm and about 260 nm, between about 260 nm and about 270 nm) or in the ultraviolet B spectrum as described above (e.g., between about 305 nm and about 315 nm). In another non-limiting embodiment, the first light source channel may emit light having a peak wavelength in the ultraviolet A spectrum as described above (e.g., between about 330 nm and about 350 nm, between about 340 nm and about 350 nm), and the second light source channel may emit light having a peak wavelength also in the ultraviolet A spectrum as described above (e.g., between about 315 nm and about 335 nm, between about 355 nm and about 375 nm). In some embodiments, the first peak wavelength is the average peak wavelength of the one or more light sources in the first light source channel. In some embodiments, the light source array may include a first light source channel, a second light source channel, and a third light source channel, each light source channel emitting light at the first peak wavelength, the second peak wavelength, and the third peak wavelength, respectively.In some embodiments, the first peak wavelength may differ from the second peak wavelength by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm or more, and / or the second peak wavelength may differ from the third peak wavelength by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm or more. Alternatively, each of the first, second, and third peak wavelengths may differ from each other by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm or more. In some embodiments, the light source array may include a first light source channel, a second light source channel, a third light source channel, and a fourth light source channel, each light source channel emitting light at the first, second, third, and fourth peak wavelengths, respectively. In some embodiments, at least two, at least three, or at least four of the first, second, third, and fourth peak wavelengths may differ from each other by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm or more. Alternatively, each of the first, second, third, and fourth peak wavelengths may differ from each other by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm or more. Alternatively, the first peak wavelength may be substantially the same as the third peak wavelength (e.g., equal to, or within ±1 nm, ±2 nm, ±3 nm, ±4 nm, or ±5 nm), the second peak wavelength may be substantially the same as the fourth peak wavelength (e.g., equal to), and the first peak wavelength may differ from the second peak wavelength by at least (e.g., greater than) 5 nm, 10 nm, 15 nm, or 20 nm.

[0095] In some embodiments, each light source channel may emit light with a narrow spectral bandwidth. For example, the full width at half maximum (FWHM) spectral bandwidth (e.g., the spectral bandwidth at the maximum peak intensity) of the light emitted by each light source channel may be less than 20 nm, less than 18 nm, less than 16 nm, less than 14 nm, less than 12 nm, less than 10 nm, less than 9 nm, less than 8 nm, less than 7 nm, less than 6 nm, or less than 5 nm. In some embodiments, the FWHM spectral bandwidth of the light emitted by each light source channel is within 10 nm less than the peak wavelength and / or within 10 nm greater than the peak wavelength (e.g., not exceeding 10 nm greater than the peak wavelength and not exceeding 10 nm less than the peak wavelength). In some embodiments, the FWHM spectral bandwidth of the light emitted by each light source channel may be greater than 1 nm, greater than 2 nm, greater than 3 nm, or greater than 4 nm, or larger. In other examples, 50% of the maximum peak intensity of the light emitted by each light source channel is within 10 nm, 9 nm, 8 nm, 7 nm, 6 nm, 5 nm, 4 nm, or 3 nm of the peak wavelength (e.g., no more than 10 nm greater than the peak wavelength, no more than 10 nm less than the peak wavelength; within 10 nm less than the peak wavelength, and within 10 nm greater than the peak wavelength). In other examples, the light intensity at 50% of the maximum peak intensity of the light emitted by each light source channel is within a spectral width of less than 20 nm, less than 18 nm, less than 16 nm, less than 14 nm, less than 12 nm, less than 10 nm, less than 9 nm, less than 8 nm, less than 7 nm, less than 6 nm, or less than 5 nm (e.g., no more than 10 nm greater than the peak wavelength, no more than 10 nm less than the peak wavelength; within 10 nm less than the peak wavelength, and within 10 nm greater than the peak wavelength). Commercially available LEDs and laser diodes are non-limiting examples of light sources that can provide such narrow spectral bandwidth illumination at the aforementioned peak wavelengths.

[0096] In some implementations, one or more of the emission peak wavelength, emission spectral bandwidth, emission duration, and emission intensity of each light source channel 508 can be adjusted or set.

[0097] The adjustment of these various light source channel parameters can be performed via control circuitry 520, which is operatively coupled (e.g., communicatively coupled) to processing chambers 502 and 504, light source array 506, and / or computer system 524. As used herein, “operatively coupled” means any wired or wireless connection between two or more components that enables the two or more components to exchange information, control commands, and / or control signals. As will be discussed in more detail below, control circuitry 520 may receive control commands and / or control signals from computer system 524 and send them to various components of processing chambers 502 and 504 to adjust or set various parameters associated with the various components of chambers 502 and 504. The adjustment of various parameters of chambers 502 and 504 may be desirable to ensure that the treatment parameters of the chambers are consistent with the treatment profile of one or more biological fluids 510. It should be appreciated that in some examples, the functionality of control circuitry 520 and / or control circuitry 520 may be included within computer system 524. In some examples, control circuitry 520 may include computer system 524 and / or the functionality of computer system 524. In some examples, control circuitry 520 may be structurally attached to processing chambers 502 and 504 (e.g., attached to the outside, top surface, and / or bottom surface of processing chambers 502 and 504). In some examples, control circuitry 520 may be integrated with processing chambers 502 and 504 (e.g., located inside processing chambers 502 and 504 or forming part of the structure of processing chambers 502 and 504).

[0098] Computer system 524 can be operatively coupled (wired or wirelessly) to control circuitry 520 and / or any of the various sensors discussed herein. The computer system may include one or more processors 544. Figure 7 644 in the middle, Figure 7 744 in the memory, 542 in the memory Figure 7 642 in Figure 7 742), Input / Output (I / O) Interface 546 ( Figure 7 646 in Figure 7 746) and User Interface (UI) 548 Figure 6 648 in the middle, Figure 7(748 in the original text). One or more processors 544 can be one or more of any type of general-purpose computer processor. Memory or computer-readable medium 542 can include readily available memory such as random access memory (RAM), read-only memory (ROM), floppy disk, hard disk, optical storage media (e.g., optical disc or digital video disc), flash drive, or any other form of local or remote digital storage device. In some examples, the non-transitory computer-readable storage medium of memory 542 can be used to store instructions for irradiating one or more biological fluids according to one or more processing distributions of one or more biological fluids, as will be discussed herein. Computer system 524 can include any kind of computer, such as a personal computer (PC), desktop computer, laptop computer, computer terminal, server computer, tablet computer, smartphone, personal digital assistant (PDA), etc. In some examples, control circuitry 520 and / or the functionality of control circuitry 520 can be included within computer system 524.

[0099] In UI 548, the user can input one or more characteristics from a set of properties of one or more biofluids (e.g., biofluid 510). Alternatively or additionally, one or more characteristics of a set of properties of one or more biofluids can be determined based on feedback input from one or more sensors used in the processing chamber (e.g., processing chamber 502, processing chamber 504) to computer system 524 and / or control circuitry 520. The characteristics in this set of properties of the biofluid may include, for example, the type of biofluid (e.g., blood products such as plasma, platelets, red blood cells; cells such as eukaryotic cells; proteins such as antibodies; vaccines), photochemical agents in the biofluid (e.g., type, volume, concentration), the volume of the biofluid, the transmittance of the biofluid, the type and / or shape of the container carrying the biofluid, and the temperature of the biofluid.

[0100] In UI 548, the user can input one or more parameters including a treatment distribution of one or more biological fluids (e.g., biological fluid 510). Alternatively or additionally, computer system 524 can automatically determine one or more parameters of one or more treatment distributions of one or more biological fluids based on a corresponding set of characteristics of one or more biological fluids (e.g., biological fluid 510). In particular, memory 542 can store a computer program including instructions that map one or more characteristics of a biological fluid to one or more parameters of a treatment distribution for each biological fluid. The instructions that map one or more characteristics of a biological fluid to one or more parameters of a treatment distribution for each biological fluid can be implemented as a set of user-programmable rules.

[0101] In some embodiments, the light source array 506 may be thermally coupled to a heat exchanger 528 (e.g., a radiator, finned radiator, or heat exchanger operatively coupled to and controlled by control circuitry 520). The heat exchanger 528 may extract heat from the array 506 facing one or more biological fluids 510, thereby minimizing the exposure of the biological fluids 510 to heat (e.g., heat that could impair biological function). Further control of the temperature of chambers 502 and 504 and / or the temperature of one or more biological fluids 510 may be provided by a heating / cooling unit 526 operatively coupled to and controlled by control circuitry 520 and configured to regulate or set the temperature of chambers 502 and 504. The heating / cooling unit 526 may be any suitable technology known in the art, such as a fan, heat pump, Peltier cooler, and / or heat pipe, or any combination of these technologies. The heating / cooling unit 526 may be external to, internal to, and / or integrated with chambers 502 and 504. For example, one or more fans may be positioned at the rear of the processing chamber to draw in air through an inlet on the outer casing of the system 500 and to exhaust air through an exhaust outlet at the rear of the outer casing.

[0102] In some embodiments, the heating / cooling unit 526 may be a heating unit or a cooling unit or a heating and cooling unit. By using the heating / cooling unit 526, the system 500 may control the heating / cooling unit 526 to maintain the temperature of the biofluid within a specific temperature range (e.g., a range of 1°C, a range of 2°C, a range of 3°C, etc.) during the treatment of the biofluid by irradiation. For example, a heat or temperature sensor may provide a temperature indication or measurement result to the control circuitry 520 or via the control circuitry 520 to the computer system 524. If the control circuitry 520 and / or the computer system 524 processes or interprets the temperature indication or measurement result as exceeding a specific threshold or condition associated with a target temperature value or distribution, the control circuitry 520 and / or the computer system 524 may instruct or command, enable, engage, or actuate the heating / cooling unit 526 to take action to regulate the temperature of chamber 502 or 504 and / or the temperature of one or more biofluids 510. For example, control circuitry 520 and / or computer system 524 may instruct or command, enable, engage, or actuate one or more fans to begin blowing air to initiate cooling, blow air faster to provide an increased cooling rate, blow air slower to provide a reduced cooling rate, or stop blowing air to stop cooling. During the treatment of the biological fluid by irradiation, the one or more fans may operate cyclically under the control of control circuitry 520 and / or computer system 524 to maintain the temperature of the biological fluid within a certain temperature range (e.g., a range of 1°C, a range of 2°C, a range of 3°C, etc.). Control circuitry 520 and / or computer system 524 may instruct or command, enable, engage, or actuate any other suitable technology known in the art, such as fans, heat pumps, Peltier coolers, and / or heat pipes, or any combination of these technologies, to take action to regulate the temperature of chamber 502 or 504 and / or the temperature of one or more biological fluids 510.

[0103] In some embodiments, the one or more fans may be located at the rear of the processing chamber. The one or more fans may blow air in a front-to-back direction, a rear-to-front direction, or both. In some embodiments, the one or more fans may draw in air to pass through the processing chamber and exhaust air through an exhaust system at the rear of the system. Inlet air to the one or more fans may enter through vents located at or near the front or side of the processing chamber, and outlet air from the one or more fans may exit through vents located at the rear of the processing chamber.

[0104] Processing chambers 502 and 504 may also include a plurality of inner surfaces configured to absorb light (e.g., each inner surface is configured to absorb light), such as one or more walls made or coated with a material that substantially absorbs light of a specific wavelength (e.g., black plastic, black silicate, black paint). Alternatively or in addition, in some embodiments, processing chambers 502 and 504 may also include one or more inner surfaces configured to reflect light (e.g., each inner surface is configured to reflect light), such as one or more walls made or coated with a material that substantially reflects light of a specific wavelength.

[0105] Processing chambers 502 and 504 may also include a platform 530 configured to hold one or more biofluids 510 (e.g., containers of biofluids). Platform 530 can be any support suitable for carrying biofluids or containers of biofluids. Platform 530 can be positioned in a "drawer configuration" such that it can be manually slidably moved into and out of chambers 502 and 504. Platform 530 can be automatically slidably moved by any suitable actuator (e.g., an electric motor or servo mechanism). Platform 530 carrying biofluid 510 may be positioned above light source array 506, with light source array 506 facing platform 530. However, in other embodiments, platform 530 carrying one or more biofluids may be positioned below light source array 506, with light source array 506 facing platform 530.

[0106] In some embodiments, system 500 includes one or more scanners 532 in processing chambers 502 and 504. When fluid is positioned for processing, one or more scanners 532 may be positioned above the biological fluid 510 (e.g., scanner 532A in the first processing chamber, scanner 532B in the second processing chamber). As shown, one or more scanners 532 (e.g., scanner 532C) may also be located outside system 500 (e.g., external housing, outer surface) between the first and second processing chambers. One or more scanners 532 may be substantially similar to the scanners described herein. In some embodiments, when the biological fluid is loaded into the respective processing chamber, the corresponding scanner in the respective chamber may obtain identification information about the biological fluid, as described herein. In some embodiments, the one or more scanners may be positioned at or near a first opening of the first processing chamber 502, at or near a second opening of the second processing chamber 504, or at or near the openings of both chambers, for example, to obtain identification information about the biological fluid before it is positioned in the respective processing chamber.

[0107] Each platform 530A and 530B can be configured to carry a first biological fluid 510A and a second biological fluid 510B, respectively, in a first container (e.g., a flexible container, a bag) and a second container (e.g., a flexible container, a bag). Each container can have a volumetric capacity, for example, up to about 3000 mL, up to about 2500 mL, up to about 2000 mL, up to about 1500 mL, up to about 1400 mL, up to about 1300 mL, up to about 1200 mL, up to about 1100 mL, up to about 1000 mL, up to about 950 mL, up to about 900 mL, up to about 850 mL, up to about 800 mL, up to about 750 mL, up to about 700 mL, up to about 650 mL, up to about 600 mL, up to about 550 mL, or up to about 500 mL.

[0108] Figure 6 This is a perspective view of an exemplary system 600 for processing biological fluids. In some embodiments, system 600 is substantially similar to... Figure 5 The system 500 shown. An exemplary system 600 for processing biological fluids includes: a first processing chamber 602 and a second processing chamber 604 for receiving one or more biological fluids 610; a first light source array 606 in each chamber positioned to illuminate one or more biological fluids 610 from below; a second light source array 608 in each chamber positioned to illuminate one or more biological fluids 610 from above; a platform 630 in each chamber configured to hold one or more biological fluids 510 (e.g., a container for the biological fluids); and a sensor (e.g., a scanner) 632 configured to acquire identification information of the biological fluids loaded into the processing chambers. The first light source array 606 and the second light source array 608, positioned above and below the one or more biological fluids 610 in each of the processing chambers 602 and 604, provide illumination of the biological fluids from one direction (i.e., above or below) or both directions (i.e., both).

[0109] System 600 may include scanners 632A and 632B, with scanner 632A positioned externally to system 600 (e.g., on the outer casing or outer surface) at a location associated with a first processing chamber 602 (e.g., at or near the opening of the first processing chamber 602), and scanner 632B positioned externally to system 600 (e.g., on the outer casing or outer surface) at a location associated with a second processing chamber 604 (e.g., at or near the opening of the second processing chamber 604), for example, to obtain identification information about the biological fluid before it is positioned within the respective processing chamber. System 600 may also include scanner 632C positioned internally to system 600 (e.g., on the inner wall, in the top plate, in the bottom plate) between the first and second processing chambers 602 and 604. In some embodiments, scanner 632C may be configured to obtain information from a container positioned in either or both processing chambers.

[0110] Figure 7 This is a perspective view of an exemplary system 700 for processing biological fluids. In some embodiments, system 700 is substantially similar to system 300 shown in Figure 3. Figure 5 The system 500 shown differs in that the first processing chamber 702 and the second processing chamber 704 are vertically positioned (above and below each other) within the system 700. An exemplary system 700 for processing biological fluids includes: a first processing chamber 702 and a second processing chamber 704 for receiving one or more biological fluids 710; a first light source array 706 in each chamber positioned to illuminate the one or more biological fluids 710 from below; a platform 730 in each chamber configured to hold the one or more biological fluids 710 (e.g., a container for the biological fluids); and a sensor (e.g., a scanner) 732 configured to acquire identification information of the biological fluids loaded into the processing chamber. The platform 730 carrying the biological fluids 710 may be positioned above the light source array 706, with the light source array 706 facing the platform 730. However, in other embodiments, the platform 730 carrying the one or more biological fluids may be positioned below the light source array 706, with the light source array 706 facing the platform 730. Each of the light source chambers 702 and 704 may further include a second light source array (not shown) positioned above and below one or more biological fluids 710, such as those similar to... Figure 6 The system shown is 600.

[0111] System 700 may include scanners 732A and 732B positioned inside a first processing chamber 702 (e.g., in a top plate above the compartments of biofluids 710A and 710B) and similarly two scanners positioned inside a second processing chamber 704 (e.g., in a top plate above the compartments of biofluids 710C and 710D). Alternatively or additionally, system 700 may include scanner 732E positioned outside system 600 (e.g., an outer housing, an outer surface) between the first and second processing chambers 702. In some embodiments, scanner 732E may be configured to obtain information from containers positioned in either or both processing chambers (e.g., when a platform in a drawer configuration is in the open position within the field of view of scanner 732E, or when an RFID tag is within the detection range of scanner 732E).

[0112] In some embodiments, any of the above-described processing systems can be used to treat one or more biological fluids (inactivating pathogens therein), preferably biological fluids mixed with one or more pathogen-inactivating compounds (e.g., photoactive pathogen-inactivating compounds, psoralen). Specifically, any of the above-described processing systems can irradiate a mixture of one or more pathogen-inactivating compounds and biological fluids such as blood or blood products (e.g., platelet compositions, plasma compositions, and derivatives thereof) with light of a specific wavelength (e.g., ultraviolet light) to induce a photochemical reaction and inactivate pathogens, such as viruses, bacteria, parasites, and other contaminants, such as cellular contaminants (e.g., leukocytes), that may be present in the biological fluid. In some embodiments, the pathogen-inactivating compounds target nucleic acids to photochemically form adducts and / or cross-links. For example, the apparatus of this disclosure can be used in a method of treating a biological fluid, the method comprising: providing a biological fluid mixed with a photoactive pathogen inactivating compound (e.g., psoralen, amtosalin); and irradiating the biological fluid with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 315 nm to about 350 nm (e.g., about 315 nm to about 335 nm, about 330 nm to about 350 nm, about 340 nm to about 350 nm, about 340 nm, about 345 nm), wherein the duration and intensity of irradiation of the biological fluid are sufficient to inactivate pathogens in the biological fluid. In some embodiments, each of the one or more first light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers. In some embodiments, each of the one or more first light sources is a light-emitting diode (LED).

[0113] The term "pathogen inactivating compound" refers to any suitable compound, such as a small molecule organic compound, that can be used to inactivate pathogens that may be present in biological fluids (e.g., blood or blood products). Pathogen inactivating compounds that are "photoactive," "photoactivated," "photochemical," or "photosensitizer" are suitable compounds that require a certain level of light to adequately inactivate pathogens. These compounds are preferred for inactivating pathogens in biological products because they provide control over the inactivation process. In some embodiments, the pathogen inactivating compound is a photoactive pathogen inactivating compound selected from the group consisting of psoralen, isorhodoxime, phosphonates, phthalocyanine, phenothiazines, porphyrins, and phthalocyanine 540. In some embodiments, the pathogen inactivating compound is psoralen. In some embodiments, the pathogen inactivating compound is amtoxalin (e.g., S-59). Such photoactivated or photochemical pathogen inactivating compounds described herein may include, but are not limited to, psoralen, isorhodoxime, phosphonates, phthalocyanine, phenothiazines, and porphyrins, wherein these terms should be understood to encompass compounds of a general category, namely the core compound and its suitable derivatives. For example, psoralen is typically described as the psoralen core compound and any of its derivatives (e.g., amtosalin), and isorhozine is typically described as the isorhozine core and any of its derivatives (e.g., riboflavin), etc. Such derivatives include the core compound structure and any additional substituents on the core. The description of such compounds includes any of their salts.

[0114] The term "amtosalicyline" refers to the compound 3-(2-aminoethoxymethyl)-2,5,9-trimethylfurano[3,2-g]chromone-7-one and any salt thereof. This compound may also be referred to as 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen. In the cases where the methods of this disclosure include the addition of amtosalicyline hydrochloride (an HCl salt of amtosalicyline), the removal of this compound from biological fluids such as blood products (e.g., platelet compositions, platelet units, plasma compositions, whole blood compositions, plasma compositions) is not limited to the removal of amtosalicyline hydrochloride, as amtosalicyline can exist in solution as other salts or as a free base. As used in the methods described herein, removal of amtosalicyline means the removal of the compound in any form, such as as a free base or as any salt, as measured by the assay methods described herein.

[0115] In some embodiments, the pathogen-inactivating compound is a 4-primary amino-substituted psoralen, which is a psoralen compound having an NH2 group at the 4'-position of psoralen linked by a hydrocarbon chain of 2 to 20 carbons in total length, wherein 0 to 6 of these carbons are independently substituted with NH or O, and each substitution site is separated from each other substitution site by at least two carbons and from psoralen by at least one carbon. The 4'-primary amino-substituted psoralen may have additional substitutions at the 4, 5', and 8 positions of psoralen, including but not limited to the following groups: H and (CH2). n CH3, where n = 0-6. In some embodiments, the 4'-primary amino-substituted psoralen comprises: a) a substituent R1 on the 4' carbon atom, which is selected from -(CH2). u -NH2、-(CH2) w -R2-(CH2) z -NH2、-(CH2) w -R2-(CH2) x -R3-(CH2)z-NH2 and -(CH2) w -R2-(CH2) x -R3-(CH2) y -R4-(CH2) z The group consisting of -NH2; wherein R2, R3, and R4 are independently selected from the group consisting of O and NH, wherein u is an integer from 1 to 10, w is an integer from 1 to 5, x is an integer from 2 to 5, y is an integer from 2 to 5, and z is an integer from 2 to 6; and b) substituents R5, R6, and R7 at the carbon atoms at positions 4, 5', and 8, respectively, which are independently selected from the group consisting of H and (CH2). v Groups of CH3, where v is an integer from 0 to 5; or salts thereof.

[0116] In some embodiments, the pathogen-inactivating compound is a 5-primary amino-substituted psoralen, which is a psoralen compound having an NH2 group at the 5'-position of psoralen linked by a hydrocarbon chain of 1 to 20 carbons in total length, wherein 0 to 6 of these carbons are independently substituted with NH or O, and each substitution site is separated from each other substitution site by at least two carbons and from psoralen by at least one carbon. The 5'-primary amino-substituted psoralen may have additional substitutions at the 4, 4', and 8 positions of psoralen, including but not limited to the following groups: H and (CH2). n CH3, where n = 0-6. In some embodiments, the 5'-primary amino-substituted psoralen comprises: a) a substituent R1 on the 5' carbon atom, which is selected from -(CH2). u -NH2、-(CH2) w -R2-(CH2) z-NH2、-(CH2) w -R2-(CH2) x -R3-(CH2)z-NH2 and -(CH2) w -R2-(CH2) x -R3-(CH2) y -R4-(CH2) z The group consisting of -NH2; wherein R2, R3, and R4 are independently selected from the group consisting of O and NH, and wherein u is an integer from 1 to 10, w is an integer from 1 to 5, x is an integer from 2 to 5, y is an integer from 2 to 5, and z is an integer from 2 to 6; and b) substituents R5, R6, and R7 on carbon atoms 4, 4', and 8, respectively, which are independently selected from the group consisting of H and (CH2). v A group of CH3, where v is an integer from 0 to 5, where R1 is selected from the group containing -(CH2). u When the group contains -NH2, R7 is (CH2). v CH3, and where R5, R6, and R7 are (CH3) 2 ) v When CH3, u is an integer from 3 to 10; or a salt thereof. Exemplary psoralen compounds are described, for example, in U.S. Patent 5,593,823.

[0117] In some embodiments, a biofluid (e.g., a platelet composition) is mixed with a pathogen-inactivating compound (PIC) in a platelet additive solution (PAS). In some embodiments, the PIC is mixed with the PAS prior to mixing with the biofluid. Platelet additive solutions are known in the art, for example, as described by Alhumaidan et al. and Ringwald et al. (Alhumaidan, H. and Sweeney, J., J Clin Apheresis, 27:93-98 (2012); Ringwald et al., Transfusion Medicine Reviews, 20:158-64 (2006)), the entire contents of which are incorporated herein by reference. In some embodiments, the platelet additive solution (PAS) comprises one or more of chloride, acetate, citrate, potassium, magnesium, phosphate, gluconate, glucose, and bicarbonate. In some embodiments, the platelet additive solution (PAS) is a PAS approved by a regulatory or certification body generally accepted in the art.

[0118] In some embodiments, the method further includes agitating the biological fluid. In some embodiments of any method disclosed herein, the total dose of ultraviolet light irradiating the biological fluid (e.g., emitted by one or more light sources, emitted by a group of one or more light sources, or emitted by an array of light sources) is approximately 0.5 J / cm². 2Approximately 50 J / cm 2 Such as approximately 0.5 J / cm 2 Approximately 10 J / cm 2 Approximately 0.5 J / cm 2 Approximately 15 J / cm 2 Approximately 0.5 J / cm 2 Approximately 25 J / cm 2 Approximately 1 J / cm 2 Approximately 10 J / cm 2 Approximately 1 J / cm 2 Approximately 15 J / cm 2 Approximately 1 J / cm 2 Approximately 25 J / cm 2 Approximately 3J / cm 2 Approximately 10 J / cm 2 Approximately 3J / cm 2 Approximately 15 J / cm 2 Approximately 3J / cm 2 Approximately 25 J / cm 2 Approximately 5 J / cm 2 Approximately 10 J / cm 2 Approximately 5 J / cm 2 Approximately 15 J / cm 2 Approximately 5 J / cm 2 Approximately 25 J / cm 2 Approximately 10 J / cm 2 Approximately 30 J / cm 2 Approximately 10 J / cm 2 Approximately 20 J / cm 2 Approximately 15 J / cm 2 Approximately 50 J / cm 2 Approximately 15 J / cm 2 Approximately 35 J / cm 2 Approximately 20 J / cm 2 Approximately 30 J / cm 2 Approximately 25 J / cm 2 Approximately 50 J / cm 2 Approximately 30 J / cm 2 Approximately 40 J / cm 2 or about 40J / cm 2 Approximately 50 J / cm 2 Any of the above. In some embodiments, the total dose of ultraviolet light irradiating the biological fluid is approximately 0.5 J / cm². 2 Or more, such as about 1 J / cm 2 or more, 2J / cm 2 or more, 3J / cm 2 or more, 4J / cm 2or more, 5J / cm 2 or more, 6J / cm 2 or more, 7J / cm 2 or more, 8J / cm 2 or more, 9J / cm 2 or more, 10J / cm 2 or more, 15J / cm 2 or more, 20J / cm 2 or more, 25J / cm 2 or more, 30J / cm 2 or more, 35J / cm 2 or more, 40J / cm 2 or more, 45J / cm 2 or more or 50 J / cm 2 One or more of these. In some embodiments, the total dose of ultraviolet light irradiating the biological fluid is less than about 50 J / cm². 2 Less than approximately 40 J / cm 2 Less than approximately 30 J / cm 2 Less than approximately 25 J / cm 2 Less than approximately 20 J / cm 2 Less than approximately 15 J / cm 2 or less than about 10 J / cm 2 In some embodiments, the duration and intensity of irradiation of the biological fluid are sufficient to inactivate pathogens in the biological fluid (e.g., if present in the biological fluid). For example, in some embodiments, the duration and intensity of irradiation of the biological fluid are sufficient to provide the desired total dose of ultraviolet light irradiating the biological fluid (e.g., the aforementioned total dose) (e.g., any suitable combination of duration and intensity sufficient to provide the total dose of ultraviolet light). In some embodiments, the intensity is 1-1000 mW / cm². 2 (For example, 1-100mW / cm) 2 In some implementations, the duration is from 1 second to 2 hours (e.g., from 1 minute to 60 minutes).

[0119] It should be understood that treating biofluids to inactivate any pathogens that may be present does not necessarily mean completely inactivating all pathogens that may be present, but rather significantly reducing the amount of pathogens to significantly reduce the risk posed by the presence of pathogens (e.g., infections associated with administration of biofluids contaminated with pathogens, transfusion-related diseases from blood products, and transfusion-transmitted infections from blood products). Pathogen inactivation can be determined by measuring the amount of infectious pathogens (e.g., viral particles, bacteria) in a given volume, and the level of inactivation is typically expressed as a logarithmic reduction in pathogen infectivity or a logarithmic reduction in titer. Methods for determining the logarithmic reduction in titer and the measurements used to assess the level of pathogen inactivation are well known in the art. In some embodiments, the systems, devices, and / or methods used for treatment are sufficient to inactivate at least 1 log (e.g., at least 2 log, at least 3 log, at least 4 log, or more) of pathogens in the biofluid (if present). In some embodiments, the irradiated biofluid is suitable for infusion into a subject without further treatment to remove residual pathogen-inactivating compounds or their photoproducts. In some embodiments, the system, apparatus, and / or method for treatment is sufficient to inactivate at least 1 log (e.g., at least 2 log, at least 3 log, at least 4 log, or more) of pathogens in the biological fluid (when present), and after irradiation, the biological fluid contains 10 μM or less of a pathogen-inactivating compound. In some embodiments, the system, apparatus, and / or method for treatment is sufficient to inactivate at least 1 log (e.g., at least 2 log, at least 3 log, at least 4 log, or more) of pathogens in the biological fluid (when present), and after irradiation, the biological fluid contains 7.5 μM or less of a pathogen-inactivating compound. In some embodiments, the system, apparatus, and / or method for treatment is sufficient to inactivate at least 1 log (e.g., at least 2 log, at least 3 log, at least 4 log, or more) of pathogens in the biological fluid (when present), and after irradiation, the biological fluid contains 5 μM or less (e.g., 4 μM or less, 3 μM or less, 2 μM or less, 1 μM or less, 0.5 μM or less) of a pathogen-inactivating compound. In some embodiments, the concentration of the pathogen-inactivating compound mixed with the biological fluid prior to irradiation is at least about 10 μM (e.g., at least about 30 μM, at least about 60 μM, at least about 90 μM, at least about 110 μM). In some embodiments, the concentration of the pathogen-inactivating compound mixed with the biological fluid prior to irradiation is about 15 μM to about 150 μM (e.g., about 30 μM to about 110 μM, about 60 μM to about 90 μM, about 75 μM). In some embodiments, the concentration of the pathogen-inactivating compound mixed with the biological fluid after irradiation is at most one-third of the concentration of the pathogen-inactivating compound mixed with the biological fluid prior to irradiation.In some implementations, the irradiated biofluid maintains sufficient biological activity to make it suitable for infusion into the subject.

[0120] Figure 8 An example of a computing device according to one embodiment is shown. Device 800 may be a host connected to a network. Device 800 may be a client computer or a server. Figure 8 As shown, device 800 can be any suitable type of microprocessor-based device, such as systems 100-700, computing system 524, personal computer, workstation, server, or handheld computing device (portable electronic device) such as a telephone or tablet computer. The device may include, for example, one or more of processor 802, input device 806, output device 808, memory 810, and communication device 804. Input device 806 and output device 808 can generally correspond to those described above and can be connected to or integrated with a computer.

[0121] Input device 806 can be any suitable device for providing input, such as any of the displays, touchscreens, keyboards or keypads, mice or voice recognition devices disclosed herein. Output device 808 can be any suitable device for providing output, such as touchscreens, haptic devices or speakers.

[0122] Storage device 810 can be any suitable device providing storage, such as electrical memory, magnetic memory, or optical memory, including RAM, cache, hard disk drive, or removable storage disk. Communication device 804 can include any suitable device capable of transmitting and receiving signals over a network, such as a network interface chip or device. Computer components can be connected in any suitable manner, such as via a physical bus or wirelessly.

[0123] The software 812, which can be stored in storage device 810 and executed by processor 802, may include, for example, programs that embody the functionality of this disclosure (e.g., as embodied in the device described above).

[0124] Software 812 may also be stored in and / or transmitted in any non-transitory computer-readable storage medium for use by or in connection with an instruction execution system, device, or apparatus, such as those described above, which may retrieve and execute instructions associated with the software from and execute such instructions. In the context of this disclosure, a computer-readable storage medium may be any medium, such as storage device 840, which may contain or store programs used by or in connection with an instruction execution system, device, or apparatus.

[0125] Software 812 can also be propagated within any transmission medium for use by or in conjunction with an instruction execution system, device, or apparatus, such as those described above, which can retrieve and execute instructions associated with the software from and execute such instructions. In the context of this disclosure, the transmission medium can be any medium capable of transmitting, propagating, or transporting a program for use by or in conjunction with an instruction execution system, device, or apparatus. Transmission readable media can include, but are not limited to, electrical, magnetic, optical, electromagnetic, or infrared wired or wireless transmission media.

[0126] Device 800 can be connected to a network, which can be any suitable type of interconnected communication system. The network can implement any suitable communication protocol and can be protected by any suitable security protocol. The network can include any suitable network link arrangement that enables the transmission and reception of network signals, such as wireless network connections, T1 or T3 lines, cable networks, DSL, or telephone lines.

[0127] Device 800 can implement any operating system suitable for operation on a network. Software 812 can be written in any suitable programming language, such as C, C++, Java, or Python. In various embodiments, application software embodying the functionality of this disclosure can be deployed in different configurations, such as in a client / server setup or via a web browser as, for example, a web-based application or web service.

[0128] Figure 9A A perspective view of system 400 is shown, revealing the outer housing at the front and the internal components from the side. Similar to... Figure 4J The side view shows: an upper level including a display 420 (e.g., a touchscreen) and control circuitry and / or a computer system; a first light source array 406 located above and facing the first platform 440 to irradiate a first biofluid on the first platform 440 in a first processing chamber; a second light source array 408 located below and facing the first platform 440 to irradiate the first biofluid positioned on the first platform 440; a third light source array 416 located above and facing the second platform 450 to irradiate a second biofluid positioned on the second platform 450 in a second processing chamber; and a fourth light source array 418 located below and facing the second platform 450 to irradiate the second biofluid positioned on the second platform 450. Similar to... Figure 4A The front-facing outer casing reveals the display 420, scanner 430, and corresponding panels 480 and 490 of platforms 440 and 450, which are in the closed position in a drawer configuration. Furthermore, Figure 9AA fan 426 positioned behind the first processing chamber and a fan 436 positioned behind the second processing chamber are shown.

[0129] Figure 9B A perspective view of system 400 is shown, revealing the outer housing at the front and the internal components from the side. Similar to... Figure 9A The front-facing outer housing shows the display 420, scanner 430, and corresponding panels 480 and 490 of platforms 440 and 450, but the platforms are in the open position in a drawer configuration. The internal areas of platforms 440 and 450, including compartments 460A and 460B, are also shown, and the external areas of platforms 440 and 450 are slidably movable into and out of the first (top) processing chamber and the second (bottom) processing chamber via external guide rails or tracks 462, respectively.

[0130] In some implementations, system 400 may include one or more access panels through which maintenance or repair personnel can access internal components or structures of system 400 and then perform maintenance or repair on the internal components or structures of the system. Figure 9C-9E An exemplary proximity panel of system 400 is shown.

[0131] Figure 9C A perspective view of system 400 is shown, illustrating the outer housing at the front and the internal components from the side. The outer housing at the front shows four proximity panels in the closed position: a user interface proximity panel 422, a top proximity panel 482, a middle proximity panel 484, and a bottom proximity panel 486. The user interface proximity panel 422 is located at the level of the touchscreen 420 and includes the touchscreen 420 and the adjacent housing area. The top proximity panel 482 is located above the first panel of the first platform 440. The middle proximity panel 484 is located between the panels of the first platform 440 and the second platform 450. The bottom proximity panel 486 is located below the second panel of the second platform 450. In other examples, a single middle proximity panel may be replaced by two middle proximity panels. Furthermore, Figure 9C A fan 426 positioned behind the first processing chamber and a fan 436 positioned behind the second processing chamber are shown.

[0132] Figure 9DA perspective view of system 400 is shown, with three of the four proximity panels in the open position. User interface proximity panel 422 remains in the closed position. Top proximity panel 482 flips upwards to the open position, and the first light source array 406 can be slidably moved into and out of system 400 through the opening in top proximity panel 482. Middle proximity panel 484 opens to the left to the open position, and the second light source array 408 and the third light source array 416 can be slidably moved into and out of system 400 through the opening in middle proximity panel 484. Bottom proximity panel 484 flips downwards to the open position, and the fourth light source array 418 can be slidably moved into and out of system 400 through the opening in bottom proximity panel 484. Through these three proximity panels, maintenance or repair personnel can access the internal components or structures of system 400 (such as the four light source arrays 406, 408, 416, 418) and then perform maintenance or repair on the internal components or structures of the system.

[0133] Figure 9E A perspective view of system 400 is shown, with one of four proximity panels in the open position. Top proximity panel 482, middle proximity panel 484, and bottom proximity panel 486 are in the closed position. User interface proximity panel 422 is flipped up to the open position, and components such as touchscreen 420 and control circuitry and / or computer systems are accessible. The back of the touchscreen can be accessed from behind the open user interface proximity panel. The control circuitry and / or computer system can be slidably moved into and out of system 400 through the opening in the open user interface proximity panel 422. Exemplary control circuitry and / or computer systems may include one or more processors, input devices, output devices, memory, and / or communication devices. Through user interface proximity panel 422, maintenance or repair personnel can access internal components or structures of system 400 (such as touchscreen 420 and control circuitry and / or computer systems) and then perform maintenance or repair on the internal components or structures of the system.

[0134] Figures 9A-9E All the implementation schemes shown can be combined with the above regarding Figure 3B Any or all of the air ventilation teachings discussed. For example, Figure 9F It shows Figure 9AOne embodiment includes a panel with air vents 485 and 495. These air vents 485 and 495 can provide one or more air inlets and / or one or more air outlets, for example, to provide cooling or heat dissipation or other temperature control functions. Air can be drawn into and / or exhausted from the system 400 by, for example, the operation of a fan 426 positioned behind a first processing chamber and a fan 436 positioned behind a second processing chamber. In some embodiments, in the absence of air ventilation or in the absence of air ventilation, the panel may be flush or substantially flush with adjacent structures (e.g., adjacent panels, adjacent frames of the outer housing, etc.), such as... Figures 9A-9F As shown.

[0135] Figures 9A-9F All the implementation schemes shown can be combined with the above regarding Figure 3B Any or all of the sides discussed are close to the panel's teaching content. Figures 9A-9F The open side view shown can be the view seen by maintenance or repair personnel when the panel is opened or removed from one or more sides.

[0136] Figure 10 Two adjacent systems 400 are shown, with one of the systems 400 also adjacent to a wall 1002 or other equipment 1004. In some embodiments, the housing of each system may have a maximum horizontal width 1010 ranging from 30cm to 60cm at any width interval. In some embodiments, the housing of each system may have a maximum horizontal width 1010 of 60cm, 58cm, 56cm, 54cm, 52cm, 50cm, 48cm, or 46cm. In some embodiments, the housing of each system may have a maximum horizontal width 1010 ranging from 30cm to 45cm. In some embodiments, the housing of each system may have a maximum horizontal width 1010 of 45cm, 43cm, 41cm, 39cm, 37cm, 35cm, 33cm, or 31cm. When the maximum horizontal width 1010 of the housing of each system decreases, the adjacent systems 400 can occupy a more compact space, which can allow the blood product processing facility to operate more systems and increase the throughput of biofluids for a given amount of space in the facility.

[0137] For each system 400, the system can be configured (e.g., according to the manufacturer's operating instructions or documentation) to operate within a target (e.g., minimum) operating space 1020, such that there are empty spaces 1012, 1014 on both the left and right sides of the housing of system 400 (e.g., any target operating space, including operating spaces such that there are 20 cm or less on both the left and right sides of the housing). The empty spaces (or minimum operating spaces) on the left and / or right sides can be 30 cm or less, 25 cm or less, 20 cm or less, 15 cm or less, 10 cm or less, or 5 cm or less, for example, about 30 cm, about 25 cm, about 20 cm, about 15 cm, about 10 cm, about 5 cm, or about 0 cm. In some embodiments, no empty space (e.g., operating space) is required on either side of the system. As the empty space between adjacent systems 400 decreases, adjacent systems 400 can occupy a more compact space, which can allow the blood product processing facility to operate more systems and increase the throughput of biofluids processed for a given amount of space in the facility. For example, due to the thermal radiation range (e.g., airflow requirements) of each adjacent prior irradiator system, the prior irradiator systems may require significantly wider empty spaces (e.g., operating spaces) on one or both sides of the system disclosed herein. An adjacent second prior irradiator system can operate appropriately outside the thermal radiation range of the first prior irradiator system without adversely increasing the target operating temperature of the adjacent second prior irradiator system due to thermal radiation from the first prior irradiator system.

[0138] Previous irradiator systems are typically wide horizontally and limited to a single horizontal processing chamber. The improved systems and methods disclosed herein can provide irradiator systems with multiple processing chambers and design features that offer various advantages, wherein the multiple processing chambers can be independently controlled and used for the processing. For example, due to the forward-backward agitation direction of the platform of system 400, the system may not require a wide housing to accommodate left-right agitation. As another example, utilizing a relatively compact and narrow form factor, multiple (e.g., two, two and a half, three) complete systems 400 can fit within the operating space of a single previous irradiator system. As yet another example, due to the front-to-back or back-to-front direction of the fan airflow, a lateral operating space to accommodate left-right airflow may not be required on the left and / or right sides of system 400. Each of these examples provides exemplary advantages over previous irradiator systems, but the improved systems and methods disclosed herein are not limited to these exemplary advantages but can provide other advantages according to this disclosure.

[0139] This disclosure provides a method for treating a biological fluid, the method comprising irradiating the biological fluid with any system provided herein (e.g., the aforementioned system, the system disclosed below), the duration and intensity of which are sufficient to inactivate pathogens in the biological fluid (e.g., if present in the biological fluid). In some embodiments, this disclosure provides a method for treating a biological fluid, the method comprising: providing a biological fluid mixed with a pathogen inactivating compound (e.g., a photoactive pathogen inactivating compound, psoralen, amtosalin), and irradiating the biological fluid with any system provided herein (e.g., the aforementioned system), the duration and intensity of which are sufficient to inactivate pathogens in the biological fluid (e.g., if present in the biological fluid). In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources (e.g., ultraviolet A, ultraviolet B, ultraviolet C, ultraviolet light having a first peak wavelength of about 315 nm to about 350 nm), wherein: 1) each of the one or more first light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers, and / or 2) each of the one or more first light sources is a light-emitting diode (LED). In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 315 nm to about 350 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 330 nm to about 350 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 340 nm to about 350 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength in the range of 345 ± 5 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength of about 315 nm to about 335 nm. In some embodiments, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources having a first peak wavelength and ultraviolet light from one or more second light sources having a second peak wavelength, wherein the second peak wavelength differs from the first peak wavelength by at least 5 nanometers. In some implementations, the duration and intensity of irradiation provide approximately 0.5 J / cm² of ultraviolet light to irradiate the biological fluid. 2 Or greater (e.g., about 0.5 J / cm) 2 Approximately 50 J / cm 2 The total dose. In some embodiments, the intensity is 1-1000 mW / cm. 2 (For example, 1-100mW / cm) 2In some embodiments, the duration is from 1 second to 2 hours (e.g., 1 minute to 60 minutes). In some embodiments, the method of treating the biological fluid is sufficient to inactivate at least 1 log of pathogens in the biological fluid. In some embodiments, the method of treating the biological fluid is sufficient to inactivate at least 4 log of pathogens in the biological fluid. In some embodiments, the biological fluid is a blood product (e.g., platelets, plasma).

[0140] Biological fluids were treated with psoralen pathogen-inactivating compounds and irradiated with the system of this disclosure. More specifically, photochemical inactivation of both viruses and bacteria was performed with psoralen-amtosalicyline (S-59) and irradiated with ultraviolet light using the system of this disclosure, which incorporates an array of ultraviolet A LEDs with emission peak wavelengths of 346 nm–349 nm. For studies evaluating virus inactivation, platelet-containing vesicular stomatitis virus (VSV) stock solution from platelet additive solution (PAS) was mixed with commercially available amtosalicyline at a nominal concentration of 150 μM. Blood System large-volume (LV) and small-volume (SV) treatments (Cerus Corp., Concord, CA). For platelets in the LV group, three triplets of 335 mL of VSV-added platelet formulation were treated and subjected to 3.9 J / cm². 2 The platelets in the SV group were irradiated with 3.6 J / cm². Three portions of the platelet preparation containing 285 mL of VSV-added were treated and subjected to irradiation. 2 Irradiation was performed. Samples were collected before and after irradiation to determine VSV titers and logarithmic viral inactivation, as well as S-59 concentrations before and after irradiation to calculate post-irradiation photoconversion and residual amisoxalin percentage. Data are shown in Table 1 below, demonstrating VSV inactivation at 4.0 ± 0.5 and 4.5 ± 0.3 log in platelet / PAS ratios in the LV and SV groups, respectively. Furthermore, the residual S-59 percentages in the LV and SV groups were 16.5 ± 1.2 and 14.3 ± 4.6, respectively (calculated based on pre-irradiation and post-irradiation data).

[0141] For studies evaluating bacterial inactivation in different blood products, platelets from plasma or platelet supplement solution (PAS) were mixed with Klebsiella pneumoniae stock solution and then diluted with commercially available amtoxarine at a concentration of 150 μM (nominal concentration). Blood System: Plasma or platelet LV processing. For plasma, Klebsiella pneumoniae-infused plasma preparations are processed... The plasma group was treated in triplicate and subjected to 6.4 J / cm². 2 Irradiation. For platelets, platelet preparations mixed with Klebsiella pneumoniae are subjected to... The platelet LV group was treated in triplicate and subjected to 3.9 J / cm². 2 Irradiation was performed. Samples were collected before and after irradiation to determine the titer of Klebsiella pneumoniae and the logarithmic inactivation of the bacteria, as well as the S-59 concentration before and after irradiation to calculate the photoconversion and residual ammonixapine percentage after irradiation. The data are shown in Table 1 below, demonstrating logarithmic inactivation of Klebsiella pneumoniae in plasma and platelet / PAS at 6.3±0.3 and 7.2±0.2, respectively. Additionally, the residual S-59 percentages for plasma and platelet / PAS were 55.8±3.6 and 15.2±1.7, respectively (calculated based on pre-irradiation and post-irradiation data).

[0142] Table 1. Inactivation of VSV and Klebsiella pneumoniae pathogens

[0143]

[0144] While specific components, configurations, features, and functions have been provided above, those skilled in the art will understand that other variations may be used. Furthermore, although features have been described in conjunction with specific embodiments, those skilled in the art will recognize that various features of the described embodiments can be combined. Moreover, aspects described in conjunction with embodiments may be independent.

[0145] Although embodiments have been fully described with reference to the accompanying drawings, it should be noted that various changes and modifications will be apparent to those skilled in the art. Such changes and modifications should be understood to be included within the scope of the various embodiments as defined in the appended claims.

[0146] After reading the foregoing description, variations of the embodiments provided herein will be apparent to those skilled in the art. It is expected that those skilled in the art will be able to appropriately employ such variations, as well as the practice of the systems, methods, and apparatuses described herein, other than those specifically described herein. Therefore, the systems, methods, and apparatuses described herein include all modifications and equivalents of the subject matter referenced in the appended claims as permitted by applicable law. Furthermore, this specification covers any combination of the foregoing elements in all possible variations thereof, unless otherwise indicated herein or otherwise clearly contradicted by the context.

[0147] In one aspect, a biofluid processing system includes: a first processing chamber configured to receive a first biofluid; a second processing chamber configured to receive a second biofluid; a first platform configured to hold the first biofluid and positioned within the first processing chamber; a second platform configured to hold the second biofluid and positioned within the second processing chamber; a first light source array and a second light source array, the first light source array positioned to irradiate the first biofluid in the first processing chamber and the second light source array positioned to irradiate the second biofluid in the second processing chamber; a display; one or more processors; and a memory including instructions that, when executed by the one or more processors, cause the one or more processors to perform a method including providing a graphical user interface (GUI) for display on the display, the graphical user interface including a plurality of GUI objects associated with processing the first biofluid by irradiation from the first light source array or with processing the second biofluid by irradiation from the second light source array.

[0148] In some aspects of the above systems, a first light source array and a second light source array are configured to irradiate a first biological fluid and a second biological fluid with ultraviolet light, respectively. In some aspects of each of the above systems, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 315 nm to about 350 nm. In some aspects of each of the above systems, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 330 nm to about 350 nm. In some aspects of each of the above systems, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 340 nm to about 350 nm. In some aspects of each of the above systems, each light source array includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength in the range of 345 ± 5 nm. In some aspects of each of the systems described above, each light source array in the light source array includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 315 nm to about 335 nm.

[0149] In some aspects of each of the above systems, for each of the light source arrays, the corresponding first light source channel includes one or more light sources, each of the one or more light sources emitting light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers.

[0150] In some aspects of each of the above systems, the system further includes: a third light source array facing in the opposite direction to the first light source array and positioned to irradiate a first biological fluid in a first processing chamber; and a fourth light source array facing in the opposite direction to the second light source array and positioned to irradiate a second biological fluid in a second processing chamber; wherein the method further includes providing a graphical user interface (GUI) for display on a display, the graphical user interface including a plurality of GUI objects associated with processing the first biological fluid by irradiation from the third light source array or with processing the second biological fluid by irradiation from the fourth light source array.

[0151] In some aspects of each of the aforementioned systems, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 315 nm to about 350 nm. In some aspects of each of the aforementioned systems, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 330 nm to about 350 nm. In some aspects of each of the aforementioned systems, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of about 340 nm to about 350 nm. In some aspects of each of the aforementioned systems, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength in the range of 345 ± 5 nm. In some aspects of each of the above systems, each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light from the array having a first peak wavelength of about 315 nm to about 335 nm.

[0152] In some aspects of each of the above systems, for each of the third and fourth light source arrays, the corresponding first light source channel includes one or more light sources, each of which emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers.

[0153] In some aspects of each of the above systems, each light source array includes one or more light sources, each of the one or more light sources being a light-emitting diode, and wherein for each light source array, the corresponding ultraviolet light is emitted by the corresponding one or more light sources.

[0154] In some aspects of each of the above systems, the first platform is slidably movable to introduce and remove a first biological fluid into and out of a first processing chamber, and the second platform is slidably movable to introduce and remove a second biological fluid into and out of a second processing chamber.

[0155] In some aspects of each of the above systems, the system also includes a housing configured to enclose a first processing chamber, a second processing chamber, a first platform, a second platform, a first light source array, a second light source array, a display, one or more processors, and a memory.

[0156] In some aspects of each of the aforementioned systems, the system further includes a scanner configured to acquire identification information associated with the first biological fluid, the second biological fluid, or both the first biological fluid and the second biological fluid. In some aspects of each of the aforementioned systems, the scanner is one of a group consisting of a barcode scanner, a QR code scanner, and an RFID scanner. In some aspects of each of the aforementioned systems, the identification information is a visible barcode or QR code on the container for containing the first biological fluid or the second biological fluid, or on at least one container in one or more containers of a multi-container assembly for containing the first biological fluid or the second biological fluid, and the method further includes acquiring the barcode or QR code on the container for containing the first biological fluid or the second biological fluid, or on at least one container in one or more containers of a multi-container assembly, via the scanner. In some aspects of each of the aforementioned systems, the scanner is configured to acquire visual identification information on the container for containing the first or second biological fluid when the container is positioned on the first or second platform, or to acquire visual identification information on at least one container of a multi-container assembly when one or more containers of a multi-container assembly for containing the first or second biological fluid are positioned on the first or second platform. In some aspects of each of the aforementioned systems, the identification information is multiple sets of visual identification information on the container for containing the first or second biological fluid or on one or more containers of a multi-container assembly for containing the first or second biological fluid, or transmitted in a transmissible form from a tag on the container for containing the first or second biological fluid or from a tag on one or more containers of a multi-container assembly for containing the first or second biological fluid, and the scanner is a multi-scan scanner configured to acquire multiple sets of identification information in a multi-scan operation. In some aspects of each of the aforementioned systems, the scanner is integrated or embedded in a fixed location within a housing and coupled to one or more processors. In some aspects of each of the above systems, the scanner is located within a first processing chamber, a second processing chamber, or both. In some aspects of each of the above systems, the scanner is located at a first opening in the first processing chamber or a second opening in the second processing chamber. In some aspects of each of the above systems, the scanner is located outside the first and second processing chambers. In some aspects of each of the above systems, the scanner is a handheld scanner wirelessly coupled to the one or more processors. In some aspects of each of the above systems, the scanner is a handheld scanner coupled to the one or more processors via a wired connection.

[0157] In some aspects of each of the above systems, the first and second processing chambers are arranged horizontally such that the first and second biofluids lie in the same plane when positioned on the first and second platforms, respectively. In some aspects of each of the above systems, the first and second processing chambers are arranged vertically such that the first and second biofluids lie in parallel planes when positioned on the first and second platforms, respectively.

[0158] In some aspects of each of the aforementioned systems, the system further includes a first panel movable between a closed position and an open position, wherein the first panel, in the closed position, covers a first opening leading to a first processing chamber, and wherein the first panel, in the open position, exposes the first opening leading to the first processing chamber, wherein the exterior of the first panel includes one or more of a protruding handle and a recessed handle. In some aspects of each of the aforementioned systems, the system further includes a first panel movable between a closed position and an open position, wherein the first panel, in the closed position, covers the first opening leading to the first processing chamber, and wherein the first panel, in the open position, exposes the first opening leading to the first processing chamber, wherein the entire exterior of the first panel does not have any handle. In some aspects of each of the aforementioned systems, the first panel is configured to be locked to remain in the closed position and is configured to unlock in response to input.

[0159] In some aspects of each of the aforementioned systems, the first platform includes a first panel. In some aspects of each of the aforementioned systems, the first platform includes: an outer region comprising: the first panel movable between a closed position and an open position, the outer region configured to remain fixed when the first panel is in the closed position, and a first support structure; and an inner region configured to move during a time period when the outer region is fixed to agitate a first biofluid, wherein the first support structure of the outer region structurally supports the inner region. In some aspects of each of the aforementioned systems, the first platform includes: an outer region comprising: the first panel movable between a closed position and an open position, the outer region configured to remain fixed when the first panel is in the closed position, and a first support structure; and an inner region configured to move during a time period when the outer region is fixed to agitate a first biofluid, wherein the first support structure of the outer region structurally supports the inner region.

[0160] In some aspects of each of the above systems, the outer region includes a motor configured to generate motion, wherein the inner region is configured to agitate the first biofluid based on the motion generated by the motor. In some aspects of each of the above systems, the system is configured to control (e.g., adjustably control) one or more aspects of the movement of the inner region to agitate the first biofluid, such as offset, velocity, acceleration, and deceleration. In some aspects of each of the above systems, the motor is located to the right or left of where the first platform will carry the first biofluid. In some aspects of each of the above systems, the motor is located in front of or behind where the first platform will carry the first biofluid.

[0161] In some aspects of each of the aforementioned systems, the second platform includes: a second panel movable between a closed position and an open position, wherein the second panel covers a second opening leading to a second processing chamber in the closed position, and exposes the second opening leading to the second processing chamber in the open position; an outer region including: a second panel movable between a closed position and an open position, the outer region being configured to remain in a fixed position when the second panel is in the closed position; a second support structure; and an inner region configured to move during a period when the outer region is in a fixed position to agitate a second biofluid, wherein the second support structure of the output region structurally supports the inner region.

[0162] In some aspects of each of the aforementioned systems, the first platform and the second platform each include a first compartment and a second compartment, the first compartment and the second compartment being configured to carry a multi-container assembly containing biofluid of the respective platform, wherein the first compartment of the first platform is configured to carry a first container of the first multi-container assembly, the first container containing the first biofluid, and wherein the first compartment is positioned such that when the first platform is positioned in the first processing chamber, the first light source array is configured to irradiate the first container; wherein the second compartment of the first platform is configured to carry one or more additional containers of the first multi-container assembly, the one or more additional containers not containing the first biofluid, and wherein the second .... When the platform is positioned in the first processing chamber, the first light source array is not configured to illuminate the one or more additional containers; wherein the first compartment of the second platform is configured to carry the first container of the second multi-container assembly, the first container containing the second biological fluid, and wherein the first compartment is positioned such that when the second platform is positioned in the second processing chamber, the second light source array is configured to illuminate the first container; and wherein the second compartment of the second platform is configured to carry one or more additional containers of the second multi-container assembly, the one or more additional containers not containing the second biological fluid, and wherein the second compartment is positioned such that when the second platform is positioned in the second processing chamber, the second light source array is not configured to illuminate the one or more additional containers.

[0163] In some aspects of each of the above systems, the display is a touchscreen configured to display a GUI comprising multiple GUI objects, and the GUI objects respond to touch input on the touchscreen. In some aspects of each of the above systems, the method further includes: receiving input associated with selection of the GUI objects; and performing a biofluid processing operation in response to receiving the input.

[0164] In some aspects of each of the systems described above, any system provided herein (e.g., the aforementioned system) can perform a method of treating one or more biological fluids, the method comprising: irradiating a first biological fluid of the one or more biological fluids with ultraviolet light emitted by a group of one or more first light sources (e.g., ultraviolet light having a first peak wavelength of about 315 nm to about 350 nm), wherein the first biological fluid is mixed with a pathogen inactivating compound (e.g., a photoactive pathogen inactivating compound, psoralen, amtoxalin), wherein: 1) each of the one or more first light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nm, and / or 2) each of the one or more first light sources is a light-emitting diode (LED); and wherein the duration and intensity of irradiation of the first biological fluid are sufficient to inactivate pathogens in the first biological fluid. In some aspects of each of the above systems, the method of treating one or more biological fluids may further include: irradiating a second biological fluid in the one or more biological fluids with ultraviolet light emitted by one or more second light sources (e.g., ultraviolet light having a second peak wavelength of about 315 nm to about 350 nm), wherein the second biological fluid is mixed with a pathogen inactivating compound (e.g., a photoactive pathogen inactivating compound, psoralen, amtoxalin), wherein: 1) each of the one or more second light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nm, and / or 2) each of the one or more second light sources is a light-emitting diode (LED); and wherein the duration and intensity of irradiation of the second biological fluid are sufficient to inactivate the pathogens in the second biological fluid.

[0165] In some aspects of each of the systems described above, each of the first platform and the second platform is configured to carry a first biological fluid and a second biological fluid respectively in a first flexible container and a second flexible container, each flexible container having a volume capacity of up to about 3000 mL (e.g., 3000 mL or less), up to about 2500 mL, up to about 2000 mL, up to about 1500 mL, up to about 1200 mL, up to about 1000 mL, or up to about 800 mL.

[0166] In some aspects of each of the above systems, the system includes a heating unit and / or a cooling unit configured to regulate or set the temperature of a first processing chamber, wherein the method further includes: controlling the heating unit / cooling unit to maintain the temperature of the first biological fluid below 2°C during irradiation treatment of the first biological fluid from a first light source array. In some aspects of each of the above systems, the method further includes: controlling the system to maintain the temperature of the first biological fluid below 2°C during irradiation treatment of the first biological fluid from a first light source array.

[0167] In some aspects of each of the above systems, the housing has a maximum horizontal width in the range of 30cm-45cm. In some aspects of each of the above systems, the system is configured to operate within a target operating space such that there is an empty space of 20cm or less on both the left and right sides of the housing.

[0168] In some aspects of each of the above systems, the system further includes one or more front proximity panels configured to provide proximity to one or more of the first light source array, the second light source array, and the one or more processors.

[0169] In another aspect, this disclosure provides a method for treating a biological fluid, the method comprising: providing a biological fluid mixed with a pathogen-inactivating compound (e.g., a photoactive pathogen-inactivating compound, psoralen, amtoxalin), and irradiating the biological fluid with any system provided herein (e.g., the aforementioned systems), the duration and intensity of irradiation being sufficient to inactivate pathogens in the biological fluid. In some aspects of each of the aforementioned systems, the biological fluid is irradiated with ultraviolet light emitted by one or more first light sources (e.g., ultraviolet light having a first peak wavelength of about 315 nm to about 350 nm), wherein: 1) each of the one or more first light sources emits light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nm, and / or 2) each of the one or more first light sources is a light-emitting diode (LED). In some embodiments, the method for treating the biological fluid is sufficient to inactivate at least 1 log of pathogens in the biological fluid. In some embodiments, the method for treating the biological fluid is sufficient to inactivate at least 4 log of pathogens in the biological fluid.

Claims

1. A biological fluid processing system, comprising: A first processing chamber, configured to receive a first biological fluid; A second processing chamber, configured to receive a second biological fluid; A first platform, configured to carry the first biological fluid and positioned within the first processing chamber; A second platform, configured to carry the second biological fluid and positioned within the second processing chamber; A first light source array and a second light source array, wherein the first light source array is positioned to irradiate the first biological fluid in the first processing chamber, and the second light source array is positioned to irradiate the second biological fluid in the second processing chamber; monitor; One or more processors; as well as The memory includes instructions that, when executed by the one or more processors, cause the one or more processors to perform a method including providing a graphical user interface (GUI) for display on the display. The GUI includes a plurality of GUI objects associated with treating a first biological fluid by irradiation from a first light source array, or with treating a second biological fluid by irradiation from a second light source array. The biological fluid processing system further includes a first panel movable between a closed position and an open position, wherein the first panel, in the closed position, covers a first opening leading to the first processing chamber, and wherein the first panel, in the open position, exposes the first opening leading to the first processing chamber; and The biological fluid processing system further includes a second panel movable between a closed position and an open position, wherein the second panel covers a second opening leading to the second processing chamber in the closed position, and wherein the second panel exposes the second opening leading to the second processing chamber in the open position.

2. The system of claim 1, wherein the first light source array and the second light source array are configured to irradiate the first biological fluid and the second biological fluid with ultraviolet light, respectively.

3. The system of claim 1 or claim 2, wherein each of the light source arrays comprises a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of 315 nm to 350 nm.

4. The system of claim 1 or claim 2, wherein each of the light source arrays comprises a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of 330 nm to 350 nm.

5. The system of claim 1 or claim 2, wherein each of the light source arrays comprises a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of 340 nm to 350 nm.

6. The system of claim 1 or claim 2, wherein each of the light source arrays comprises a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of 315 nm to 335 nm.

7. The system of any one of claims 2 to 6, wherein each of the light source arrays comprises a corresponding first light source channel, the corresponding first light source channel comprising one or more light sources, each of the one or more light sources emitting light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers.

8. The system as described in any one of claims 1 to 7, further comprising: A third light source array, facing in the opposite direction to the first light source array and positioned to irradiate the first biological fluid in the first treatment chamber; A fourth light source array, which faces the opposite direction to the second light source array and is positioned to irradiate the second biological fluid in the second processing chamber; The method further includes providing a graphical user interface (GUI) for display on the display, the GUI including a plurality of GUI objects associated with treating the first biological fluid by irradiation from the third light source array, or with treating the second biological fluid by irradiation from the fourth light source array.

9. The system of claim 8, wherein each of the third and fourth light source arrays includes a corresponding first light source channel configured to emit ultraviolet light of the array having a first peak wavelength of 315 nm to 350 nm.

10. The system of claim 9, wherein for each of the third and fourth light source arrays, the corresponding first light source channel comprises one or more light sources, each of the one or more light sources emitting light having a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers.

11. The system of any one of claims 2 to 10, wherein each of the light source arrays comprises one or more light sources, each of the one or more light sources being a light-emitting diode, and For each of the light source arrays, the corresponding ultraviolet light is emitted by one or more corresponding light sources.

12. The system of any one of claims 1 to 11, wherein the first platform is slidably movable to introduce and remove the first biofluid into and out of the first processing chamber, and the second platform is slidably movable to introduce and remove the second biofluid into and out of the second processing chamber.

13. The system of any one of claims 1 to 12, further comprising a housing, wherein: The housing is configured to enclose the first processing chamber, the second processing chamber, the first platform, the second platform, the first light source array, the second light source array, the display, the one or more processors, and the memory.

14. The system of claim 13, wherein the housing of the system has a maximum horizontal width in the range of 30cm-45cm.

15. The system of claim 13 or 14, wherein the system is configured to operate within a target operating space such that there is an empty space of 20 cm or less on both the left and right sides of the housing of the system.

16. The system of any one of claims 13 to 15, further comprising: A scanner configured to obtain identification information associated with the first biological fluid, the second biological fluid, or both the first biological fluid and the second biological fluid.

17. The system of claim 16, wherein the scanner is one of the group consisting of a barcode scanner, a QR code scanner, and an RFID scanner.

18. The system of claim 16 or claim 17, wherein: The identification information is a visible barcode or QR code on the container for containing the first or second biological fluid, or on at least one container in a multi-container assembly for containing the first or second biological fluid. The method further includes obtaining, by the scanner, the barcode or the QR code on the container for containing the first biological fluid or the second biological fluid, or on at least one container in one or more containers of the multi-container assembly.

19. The system of any one of claims 16 to 18, wherein the scanner is configured to obtain the identification information in a visible form on the container for containing the first biological fluid or the second biological fluid when the container for containing the first biological fluid or the second biological fluid is positioned on the first platform or the second platform, or to obtain the identification information in a visible form on at least one of the containers of the multi-container assembly when the one or more containers of the multi-container assembly for containing the first biological fluid or the second biological fluid are positioned on the first platform or the second platform.

20. The system as claimed in any one of claims 16 to 19, wherein: The identification information is in the form of multiple sets of visible identification information on the container for containing the first or second biological fluid, or on one or more containers of a multi-container assembly for containing the first or second biological fluid, or transmitted in a transmissible form from a tag on the container for containing the first or second biological fluid, or from a tag on the one or more containers of the multi-container assembly for containing the first or second biological fluid. The scanner is a multi-scan scanner configured to obtain the multiple sets of identification information in a multi-scan operation.

21. The system of any one of claims 16 to 20, wherein the scanner is integrated or embedded in a fixed location within the housing and coupled to the one or more processors.

22. The system of any one of claims 16 to 21, wherein the scanner is located in the first processing chamber, the second processing chamber, or both the first processing chamber and the second processing chamber.

23. The system of any one of claims 16 to 21, wherein the scanner is located at a first opening of the first processing chamber or a second opening of the second processing chamber.

24. The system of any one of claims 16 to 21, wherein the scanner is located outside the first processing chamber and the second processing chamber.

25. The system of any one of claims 16 to 20, wherein the scanner is a handheld scanner wirelessly coupled to the one or more processors.

26. The system of any one of claims 16 to 20, wherein the scanner is a handheld scanner coupled to the one or more processors via a wired connection.

27. The system as claimed in any one of claims 1 to 26, wherein: The first processing chamber and the second processing chamber are arranged horizontally such that the first biological fluid and the second biological fluid are located in the same plane when they are positioned on the first platform and the second platform, respectively.

28. The system as claimed in any one of claims 1 to 26, wherein: The first processing chamber and the second processing chamber are arranged vertically such that the first biological fluid and the second biological fluid are located in a parallel plane when they are positioned on the first platform and the second platform, respectively.

29. The system of any one of claims 1 to 28, wherein the exterior of the first panel includes one or more of a protruding handle and a recessed handle.

30. The system of any one of claims 1 to 28, wherein the entire exterior of the first panel has no handle.

31. The system of any one of claims 29 to 30, wherein the first panel is configured to be locked to remain in the closed position and is configured to unlock in response to input.

32. The system of any one of claims 29 to 31, wherein the first platform includes the first panel.

33. The system of any one of claims 29 to 32, wherein the first platform comprises: The outer region includes: The first panel is movable between a closed position and an open position, and the outer area is configured to remain in a fixed position when the first panel is in the closed position. First supporting structure; and An internal region is configured to move during a time period when the external region is in a fixed position to agitate the first biofluid. The first support structure of the outer region structurally supports the inner region.

34. The system of claim 33, wherein the outer region includes a motor configured to generate motion, and wherein the inner region is configured to agitate the first biofluid based on the motion generated by the motor.

35. The system of claim 34, wherein the motor is located to the right or left of the point on which the first platform will carry the first biofluid.

36. The system of claim 34, wherein the motor is located in front of or behind the point on the first platform where the first biofluid will be carried.

37. The system of any one of claims 29 to 36, wherein the exterior of the second panel includes one or more of a protruding handle and a recessed handle, or the entire exterior of the second panel does not have any handle.

38. The system of any one of claims 33 to 37, wherein the second platform comprises: The outer region includes: The second panel is movable between a closed position and an open position, and the outer area is configured to remain in a fixed position when the second panel is in the closed position. Second support structure; and An internal region, configured to move during a time period when the external region is in a fixed position, to agitate the second biofluid. The second support structure in the outer region structurally supports the inner region.

39. The system of any one of claims 1 to 38, wherein the first platform and the second platform each include a first compartment and a second compartment, the first compartment and the second compartment being configured to carry a multi-container assembly accommodating the biofluid of the respective platform. The first compartment of the first platform is configured as a first container to carry a first multi-container assembly, the first container containing the first biological fluid, and wherein the first compartment is positioned such that when the first platform is positioned in the first processing chamber, the first light source array is configured to illuminate the first container. The second compartment of the first platform is configured to carry one or more additional containers of the first multi-container assembly, the one or more additional containers not containing the first biological fluid, and wherein the second compartment is positioned such that when the first platform is positioned in the first processing chamber, the first light source array is not configured to illuminate the one or more additional containers. The first compartment of the second platform is configured as a first container carrying a second multi-container assembly, the first container containing the second biological fluid, and wherein the first compartment is positioned such that when the second platform is positioned in the second processing chamber, the second light source array is configured to irradiate the first container; and The second compartment of the second platform is configured to carry one or more additional containers of the second multi-container assembly, the one or more additional containers not containing the second biological fluid, and wherein the second compartment is positioned such that when the second platform is positioned in the second processing chamber, the second light source array is not configured to illuminate the one or more additional containers.

40. The system of claim 39, wherein the first platform and the second platform each include a movable tray disposed in the platform, and wherein each movable tray includes a first compartment and a second compartment of the respective platform.

41. The system of any one of claims 1 to 40, wherein the display is a touchscreen configured to display the GUI including the plurality of GUI objects, and the GUI objects respond to touch input on the touchscreen.

42. The system of any one of claims 1 to 41, wherein the method further comprises: Receives input associated with the selection of a GUI object; as well as In response to receiving the input, a biological fluid processing operation is performed.

43. The system of any one of claims 1 to 42, wherein the method further comprises: The first biological fluid is irradiated with ultraviolet light emitted by one or more first light sources. The first biological fluid is mixed with a pathogen inactivating compound. in: 1) Each of the one or more first light sources emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers, or 2) Each of the one or more first light sources is a light-emitting diode (LED) and The duration and intensity of irradiation of the first biological fluid are sufficient to inactivate the pathogens in the first biological fluid.

44. The system of claim 43, wherein the method further comprises: The second biological fluid is irradiated with ultraviolet light emitted by one or more second light sources. The second biological fluid is mixed with a pathogen inactivating compound. in: 1) Each of the one or more second light sources emits light with a full width at half maximum (FWHM) spectral bandwidth of less than 20 nanometers, or 2) Each of the one or more second light sources is a light-emitting diode (LED), and The duration and intensity of irradiation of the second biological fluid are sufficient to inactivate the pathogens in the second biological fluid.

45. The system of any one of claims 1 to 44, wherein each of the first platform and the second platform is configured to carry the first biofluid and the second biofluid in a first flexible container and a second flexible container, respectively, each flexible container having a volumetric capacity of up to about 1500 mL.

46. ​​The system of any one of claims 1 to 45, wherein the system includes a heating unit and / or a cooling unit configured to adjust or set the temperature of the first processing chamber, wherein the method further includes: During the treatment of the first biofluid by irradiation from the first light source array, the heating / cooling unit is controlled to maintain the temperature of the first biofluid at 2°C. o C inside.

47. The system of any one of claims 1 to 46, wherein the method further comprises: During the treatment of the first biological fluid by irradiation from the first light source array, the system is controlled to maintain the temperature of the first biological fluid at 2°C. o C inside.

48. The system of any one of claims 1 to 47, further comprising one or more fans located at the rear of the first processing chamber and / or the second processing chamber, and configured to draw in air through an inlet on the outer housing of the system and to exhaust air through an exhaust outlet on the rear of the outer housing.

49. The system of claim 48, wherein the inlet comprises air ventilation on the first panel and / or the second panel.

50. The system of any one of claims 1 to 49, further comprising one or more front proximity panels configured to provide proximity to one or more of the first light source array, the second light source array, and the one or more processors.

51. The system of any one of claims 1 to 50, further comprising: A control circuit, which is operatively coupled to both the first light source array and the second light source array.

52. A method for treating biological fluids, comprising: The biological fluid is provided in combination with a pathogen-inactivating compound, and Irradiate the biological fluid with the system of any one of claims 1 to 51, wherein the duration and intensity of irradiation are sufficient to inactivate pathogens in the biological fluid.

Images